Wayne State University
Wayne State University Dissertations

1-1-2015

Therapeutic Targeting Of Bmp2 In Nf1-Deficient
Malignant Peripheral Nerve Sheath Tumors
(mpnsts)
Sidra Ahsan
Wayne State University,

Follow this and additional works at: https://digitalcommons.wayne.edu/oa_dissertations
Part of the Molecular Biology Commons, and the Pharmacology Commons
Recommended Citation
Ahsan, Sidra, "Therapeutic Targeting Of Bmp2 In Nf1-Deficient Malignant Peripheral Nerve Sheath Tumors (mpnsts)" (2015). Wayne
State University Dissertations. 1390.
https://digitalcommons.wayne.edu/oa_dissertations/1390

This Open Access Dissertation is brought to you for free and open access by DigitalCommons@WayneState. It has been accepted for inclusion in
Wayne State University Dissertations by an authorized administrator of DigitalCommons@WayneState.

THERAPEUTIC TARGETING OF BMP2 IN NF1-DEFICIENT MALIGNANT
PERIPHERAL NERVE SHEATH TUMORS
by
SIDRA AHSAN
DISSERTATION
Submitted to the Graduate School
of Wayne State University,
Detroit, Michigan
in partial fulfillment of the requirements
for the degree of
DOCTOR OF PHILOSOPHY
2015
MAJOR: CANCER BIOLOGY
Approved By:

Advisor

Date

© COPYRIGHT BY
SIDRA AHSAN
2015
All Rights Reserved

DEDICATION
This work is dedicated to my parents
For Ammi: Thank you for always being there for me. I would not have been able
to complete this without your tremendous support and encouragement. Your
strength and resilience has always inspired me to never give up.
For Abbu: Even though you are not here amongst us, your zest for life, kindness,
patience, and gentle character inspires me to do better each day.

ii

ACKNOWLEDGEMENTS
I would like to acknowledge my mentor Dr. Michael A. Tainsky for his invaluable
guidance and support towards my training as a scientist. Thank you for providing me with
countless opportunities to learn scientific techniques, participate in grant writing,
encouraging internships and professional development opportunities. Most of all, thank
you for allowing me to evolve into an independent thinker and teaching me how to ask
complex scientific questions and answer them in a logical manner.
I would like to express tremendous gratitude to my committee members, who have
contributed immensely to this project. This work would not have been possible without
your insights and guidance. I would like to acknowledge Dr. Yubin Ge for helping me
understand and design the cell viability studies. Thank you for always having your door
open for questions and discussions. I would like to thank Dr. Raymond Mattingly and Dr.
John Reiners Jr. for their input and advice on the pharmacology studies. Thank you for
your dedication to this project and my training as a graduate student.
I would like to acknowledge and thank the WSU SOM Cancer Biology graduate
program for their continuous financial support and funding of my graduate degree. I would
like to acknowledge Dr. Matherly and Dr. Brush for their guidance through the PhD
process and always taking time out of their busy schedules to address my concerns.

iii

TABLE OF CONTENTS
Dedication……………………………………………………………………………………….ii
Acknowledgments…………………………………………………………………………….iii
List of Tables………………………………………………………………………………….viii
List of Figures……………………………………………………………………………….....ix
List of Abbreviations………………………………………………………………………….xi
CHAPTER I Introduction .............................................................................................. 1
1.1 Hereditary Cancers .................................................................................................. 3
1.2 Neurofibromatosis Type I (NF1) ............................................................................... 4
1.3 Malignant Peripheral Nerve Sheath Tumors (MPNSTs) ........................................... 6
1.4 Role of NF1 in MPNSTs ........................................................................................... 7
1.5 Role of microenvironment in NF1-related malignancies ........................................... 8
1.6 Neurofibromin (Nf1) gene and function .................................................................... 9
1.7 Signaling pathways regulated by NF1 .................................................................... 12
1.7.1 Ras pathway ............................................................................................... 12
1.7.2 RAF-MEK-ERK and PI3K-AKT-MTOR axis ................................................. 13
1.7.3 RAS-independent pathways in NF1-related malignancies .......................... 16
1.8 Clinical management of MPNSTs........................................................................... 17
1.9 The case for targeting BMP2-SMAD1/5/8 signaling in NF1-related MPNSTs ........ 19
1.10 Bone Morphogenetic Protein 2 (BMP2) ................................................................ 22
1.11 Biological functions of BMP2 ................................................................................ 24
1.12 Regulation of BMP2 ............................................................................................. 25
1.12.1 Molecular inhibitors of BMP2/SMAD Signaling .......................................... 25

iv

1.12.2 Transcriptional regulation of Bmp2 ............................................................ 25
1.13 Significance of BMP2 in tumorigenesis ................................................................ 26
1.14

Proposed role of BMP2 in development of NF1-related neurofibromas and
MPNSTs… ........................................................................................................... 28

1.15 Project Overview .................................................................................................. 30
CHAPTER II Regulation of BMP2 by NF1 in MPNSTs.............................................. 33
2.1 Summary ................................................................................................................ 33
2.2 Materials and Methods ........................................................................................... 34
2.2.1 Cell culture and cell lines .............................................................................. 34
2.2.2 Lentivirus shRNA mediated stable Nf1 knockdown and inducible Nf1
knockdown system ...................................................................................... 34
2.2.3 Western blot analysis .................................................................................. 35
2.2.4 ELISA test for secreted BMP2 protein ......................................................... 36
2.2.5 RNA extraction and quantitative real time PCR ........................................... 36
2.2.6 Statistical Analyses………….…….………………………………...……………37
2.3 Results ................................................................................................................... 37
2.3.1 BMP2 is up-regulated in MPNSTs, independent of cell passaging effects .. 37
2.3.2 BMP2 is regulated by NF1 in MPNST cells ................................................. 44
2.3.2.1 Increased BMP2 expression upon down-regulation of neurofibromin.
...................................................................................................... 44
2.3.2.2 Changes in BMP2 levels are dependent on NF1 status in an inducible
Nf1 knockdown system ................................................................. 50
2.4 Conclusions ............................................................................................................ 57

v

CHAPTER III Therapeutic efficacy of targeting BMP2 and MEK1/2 signaling in
MPNSTs........................................................................................................................ 59
3.1 Summary ................................................................................................................ 59
3.2 Materials and Methods ........................................................................................... 60
3.2.1 Western blot analysis .................................................................................. 60
3.2.2 In vitro cytotoxicity assays ........................................................................... 61
3.2.3 Wound healing Assay:................................................................................. 61
3.2.4 In vitro cell invasion assay: ......................................................................... 62
3.2.5 Statistical Analyses……………….…………………………………………………….64
3.3 Results ................................................................................................................... 64
3.3.1 LDN-193189 inhibits BMP2-SMAD1/5/8 signaling ...................................... 64
3.3.2 Selumetinib inhibits MEK1/2 signaling in MPNST cells ............................... 66
3.3.3 Selumetinib synergizes with LDN-193189 to decrease viability of MPNST
cells…………………………………………………………………….………….70
3.3.4 The effects of combinatorial targeting of BMP2 and MEK1/2 signaling
pathways on cellular migration and invasion in MPNSTs ...................................... 78
3.3.4.1 Combinatorial treatment with LDN-193189 and selumetinib does not
affect cellular migration of Nf1(-/-) MPNST cells ............................. 78
3.3.4.2 Combinatorial treatment with LDN-193189 and selumetinib does not
affect cellular invasion of Nf1(-/-) MPNST cells ............................... 85
3.4 Conclusions ............................................................................................................ 91
CHAPTER IV Mechanistic studies of BMP2 regulation by NF1 in MPNSTs .......... 94
4.1 Summary ................................................................................................................ 94

vi

4.2 Materials and Methods ........................................................................................... 95
4.2.1 Construction of plasmids ............................................................................. 95
4.2.2 Promoter assays and transient transfections .............................................. 95
4.2.3 Bmp2 3’UTR analysis and transient transfections ....................................... 96
4.2.4 RNA extraction and quantitative real time PCR ........................................... 97
4.3 Results ................................................................................................................... 98
4.3.1 NF1 does not regulate Bmp2 promoter activity in MPNST cells .................. 98
4.3.2 The post-transcriptional regulation of Bmp2 by NF1 ................................. 101
4.3.2.1 NF1 regulates Bmp2 mRNA stability ........................................... 101
4.3.2.2 NF1 regulates Bmp2 3’UTR......................................................... 106
4.4 Conclusions……………………………………………………………..………...…………107
CHAPTER V Discussion .......................................................................................... 113
References ................................................................................................................. 119
Abstract……………………………………………………………………………...……….137
Autobiographical Statement .................................................................................... 147

vii

LIST OF TABLES
Table 1: Primer sequences used for gene expression studies by qRT-PCR ................ 37
Table 2: CI values for combination treatment of MPNST cells ..................................... 77
Table 3: Primer sequences used to determine Bmp2 half-life by qRT-PCR ................. 97
Table 4: Comparison of Bmp2 mRNA half-lives between Nf1(+/-) and Nf1 KD cells .... 105

viii

LIST OF FIGURES

Figure 1.1: Domains of Neurofibromin I (NF1) ............................................................. 11
Figure 1.2: Prominent NF1-related RAS-associated signaling pathways ..................... 15
Figure 1.3: Bmp2 expression levels in various stages of NF1-related Schwannomas . 21
Figure 1.4: Signaling cascade of BMP and TGF-β pathway ......................................... 23
Figure 1.5: Pathway analysis of gene expression changes upon Nf1 knockdown in
MPNSTs .................................................................................................. 32
Figure 2.1: Quantitative RT-PCR of Bmp2 mRNA in MPNST cells .............................. 39
Figure 2.2: Activation of SMAD1/5/8 and MEK1/2-ERK1/2 pathways in MPNST cells . 42
Figure 2.3: Secreted levels of BMP2 in NF1-null MPNST cells .................................... 43
Figure 2.4: Bmp2 mRNA changes upon Nf1 knockdown ............................................. 47
Figure 2.5: Activation of BMP2-SMAD1/5/8 pathway is dependent on NF1 levels ....... 48
Figure 2.6: Secreted levels of BMP2 are regulated by NF1 ......................................... 49
Figure 2.7: RFP expression in doxycycline-treated conditional Nf1 KD cells ............... 51
Figure 2.8: Quantitative RT-PCR of Bmp2 mRNA in conditional Nf1 knockdown cells . 54
Figure 2.9: BMP2-SMAD1/5/8 pathway is activated upon induction of Nf1 shRNA ...... 55
Figure 2.10: Secretion of BMP2 is regulated by NF1 in conditional Nf1-KD cells......... 56
Figure 3.1: Efficacy of LDN-193189 in inhibiting BMP2-SMAD1/5/8 signaling ............. 68
Figure 3.2: Efficacy of selumetinib (AZD6244) in inhibition of MEK1/2-ERK1/2 signaling.
................................................................................................................... 69
Figure 3.3: Analysis of inhibition of BMP2 by LDN-193189 and MEK1/2 by selumetinib
(AZD6244) upon 48 hours of drug treatments ............................................ 71
ix

Figure 3.4: The combinatorial effects of LDN-193189 and selumetinib (AZD6244) on cell
viability in STS26T-V(Nf1+/-) and STS26T-Nf1 KD cells ............................ 74
Figure 3.5: The combinatorial effects of LDN-193189 and selumetinib (AZD6244) on cell
viability in low and high passage ST88-14(Nf1-/-) cells .............................. 75
Figure 3.6: The combinatorial effects on cell viability of LDN-193189 and selumetinib
(AZD6244) in low and high passage T265(Nf1-/-) cells .............................. 76
Figure 3.7: The combinatorial treatment with LDN-193189 and selumetinib (AZD6244)
does not affect cellular motility in LP ST88-14(Nf1-/-) cells ........................ 81
Figure 3.8: The combinatorial treatment with LDN-193189 and selumetinib (AZD6244)
does not affect cellular motility in LP-T265 (Nf1-/-) cells ............................ 82
Figure 3.9: The combinatorial treatment with LDN-193189 and selumetinib (AZD6244)
does not affect cellular motility in HP ST88-14(Nf1-/-) cells ....................... 83
Figure 3.10: The combinatorial treatment with LDN-193189 and selumetinib (AZD6244)
does not affect cellular motility in HP T265(Nf1-/-) cells ............................ 84
Figure 3.11: LDN-193189 rescues the effects of BMP2 on cellular invasion in MPNST
cell lines ................................................................................................... 87
Figure 3.12: The effects of combination treatment with LDN-193189 and selumetinib
(AZD6244) on the invasion of Nf1(-/-) MPNST cells ................................ 90
Figure 4.1: NF1 does not regulate activity of the Bmp2 promoter in MPNSTs ........... 100
Figure 4.2: The rate of Bmp2 mRNA decay decreases upon NF1 downregulation in
MPNST cells .......................................................................................... 104
Figure 4.3: Activity of the Bmp2 3’UTR upon Nf1 down-regulation ............................ 108
Figure 4.4: Human Bmp2 3’UTR with associated ARE and miR-response elements . 111
Figure 5.1:

Diagram summarizing the proposed combinatorial targeted therapeutic
approach for treatment of MPNSTs ....................................................... 118

x

LIST OF ABBREVIATIONS
AKT: AK mouse strain T-thymoma
ALK: Activin-receptor-Like-Kinase

AU: Adenylate-Uridylate
Bl: Bliss Independence
BMP: Bone morphogenetic protein
CI: Combination Indice
CSRD: cysteine and serine rich domain

Dox: Doxycycline
ECM: Extracellular cellular matrix
EGFR: Epidermal growth factor receptor
ERK: Extracellular signal-related kinase
FDA: Food and drug administration

GAP: GTPase activating protein
GBM: Glioblastoma multiforme
GC: Guanine Cytosine

xi

GEF: Guanine nucleotide exchange factor
GFP: Green fluorescent protein
GRD: GAP-related domain
HP: high passage
ID: Inhibitor of Differentiation

JNK2: Janus Kinase 2
Kdecay: decay rate constant
LP: low passage
MAPK: Mitogen-activated protein kinase
miR: microRNA
MEK: Mitogen-activated protein/Extracellular signal-related kinase Kinase
MPNST: Malignant peripheral nerve sheath tumor

mTOR: mammalian Target Of Rapamycin
MTT: 3-[4,5-dimethyl-thiazol-2-yl]-2,5-diphenyltetrazolium-bromide
NF1: neurofibromin I
NF1: Neurofibromatosis Type I

xii

NSCLC: non-small cell lung carcinoma

PARP: poly(ADP-ribose) polymerase
PH: PH-like domain
PI3K: Phosphoinositide 3-Kinase
PTEN: Phosphatase and Tensin homolog
qRT-PCR: quantitative Real time-polymerase chain reaction

RAF: Rapidly Accelerated Fibrosarcoma
RFP: Red fluorescent protein
SDS-PAGE: SDS-polyacrylamide gel electrophoresis
Sec: Sec-14 domain
SMAD: Small Mothers Against Decapentaplegic
ssDNA: single stranded DNA

STAT3: Signal Transducer and Activator of Transcription-3

SYN: Syndecan binding region
TF: Transcription factor
TGF-β: Transforming Growth Factor-beta

xiii

TNF-α: Tumor Necrosis Factor-alpha
TSG: Tumor suppressor gene
TSS: Transcription start site
TUB: Tubulin binding domain
t1/2 : half-life
UTR: Untranslated region
Wnt: Wingless/int

xiv

1

CHAPTER I: Introduction
Malignant peripheral nerve sheath tumor (MPNST) is a rare form of cancer that
originates from Schwann cells associated with the peripheral nerves. MPNST accounts
for 5-10% of all soft tissue sarcomas (Strauss et al. 2001), which may occur sporadically
or in association with Neurofibromatosis Type I (NF1). Up to half of MPNST cases are
diagnosed in people with NF1 (King et al. 2000), and NF1 patients have an 8-13% chance
of developing MPNSTs (Anghileri et al. 2006). NF1 is an autosomal dominant hereditary
disorder due to loss of function in one parental copy of the neurofibromin (Nf1) gene,
which predisposes individuals to a variety of disorders including MPNSTs as well as
musculoskeletal abnormalities, developmental and cognitive disorders, and other cancer
subtypes. Nf1 is a tumor suppressor gene, which encodes for a RAS-GTPase activating
protein (GAP) related domain (GRD) that negatively regulates Ras signaling by
accelerating the hydrolysis of the active GTP-bound RAS (Xu et al. 1990). Neurofibromin
deficiency results in constitutively active Ras signaling, which plays a central role in
development and maintenance of NF1-related tumors.
MPNSTs are bulky, complex, debilitating tumors with grave prognosis. Mortality
associated with MPNSTs is primarily due to its aggressive invasiveness and motility.
Surgery is the primary treatment option for MPNSTs; however its success is limited by
tumor infiltration, resulting in a high relapse rate. Due to the size and location of MPNSTs,
surgery is often performed with wide margins, leaving behind cancer cells needing
additional chemotherapy. Based on the crucial role of NF1 RAS-GRD in development of
MPNSTs, therapies have been targeted towards the RAS-driven oncogenic pathways;
however these therapeutic strategies have met with limited success.
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The NF1-mediated regulation of Ras pathway is controlled by RAS-GRD (330
amino acids), which comprises a small portion of the NF1 protein that contains 2818
amino acids. The function of other NF1 domains is not very clear, and represents an
understudied aspect of NF1-related pathologies. Interestingly, various single nonsense
and missense mutations in the Nf1 gene outside the GRD sequence can lead to NF1
disease manifestation in patients (Messiaen & Wimmer 2008). Another study reported
that induced expression of Nf1 RAS-GRD does not rescue the lethality associated with
Nf1(-/-) mouse models (Ismat et al. 2006), suggesting that NF1 regulates vital mechanisms
of development and tumorigenesis, independently of RAS-GRD. This project addresses
the need to understand the functionality of NF1 in cancer cellular processes, independent
of RAS-GRD, which can be employed as a therapeutic strategy in NF1-related MPNSTs.
Our lab conducted a systematic gene expression profiling study using MPNST cell
lines with variable NF1 statuses to identify signaling cascades associated with NF1
malignancy, but independent of RAS-MEK1/2 signaling, to identify novel druggable
targets for MPNSTs. In doing so, we have identified the bone morphogenetic protein 2,
BMP2-SMAD1/5/8 signaling pathway, independent of the RAS-MEK1/2 regulation, as a
therapeutic target in MPNSTs (Sun et al. 2013). The functional significance of targeting
BMP2-SMAD1/5/8 signaling is demonstrated by the reversal of invasiveness and cellular
motility in MPNST cell lines by inhibition of BMP2 (Sun et al. 2013). Gene expression
data mined by our lab from NF1 patient tissue samples independently established that
increased expression of BMP2 is associated with the degree of malignancy in Schwann
cell-related tumors in NF1 patients (Miller et al. 2009).
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In this study, I present the case for targeting of BMP2-SMAD1/5/8 signaling based
on its role in motility and invasiveness in combination with current therapeutic strategies
in MPNSTs. To design a rational targeted therapeutic approach, identification of the
regulatory mechanisms leading to over-expression of BMP2 upon NF1 deficiency is
warranted. To provide a comprehensive understanding of targeting BMP2-SMAD1/5/8
signaling in MPNSTs, we assessed the feasibility of targeting BMP2 at the protein level,
and identified genetic targets mediating the increase in BMP2 signaling upon NF1
deficiency. The aim of this project is to utilize gene expression profiling studies to identify
a novel druggable target, understand the regulatory mechanisms, and therapeutic utility
of multiple targeted pathways in NF1-related MPNSTs.
1.1 Hereditary Cancers
Cancer is a disease of underlying genomic alterations.

Mutations within the

genetic material in tumor cells drive the initiation, progression, and evolution of cancers.
Loss of function mutations result in deficient or complete loss of activity in proteins such
as tumor suppressors, whereas gain of function mutations in oncogenes enhance protein
activity. Accumulation of mutations in genes that maintain genomic stability is a hallmark
of cancer. These genomic aberrations are mostly sporadic in nature, however some
mutations can be inherited from parents to offspring.
Approximately 5-10% of cancers are caused by hereditary mutations (Garber &
Offit 2005). The mechanism of genetic predisposition to cancer was described in the
early 1970s, based on studies of hereditary retinoblastoma families, which led to the
generation of the Knudson “two-hit” model of tumorigenesis (Knudson 1971).

The

Knudson model proposes that patients with hereditary susceptibility to cancers inherit
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only one functional copy of the gene. Due to genomic instability or loss of heterozygosity,
the affected patients lose the last functional copy of the gene resulting in absence of
protein function (Knudson 1971), and ultimately leading to tumorigenesis. It is important
to note that the Knudson model is specific to tumor suppressor genes (TSGs). Loss-offunction mutations are characteristic of TSGs, which require mutations in both alleles of
a gene prior to manifestation of an effect. In contrast, gain-of function mutations occur in
oncogenes where mutations in a single parental allele of a gene can result in novel or
enhanced protein functionality.
Mutations within TSGs comprise the greatest proportion of inherited susceptibility
to cancer (Hodgson 2008). These mutations often occur in pathways that regulate
essential cellular processes including chromosomal stability (e.g. p53), DNA damage
repair (e.g. BRCA1, MLH1) and cell cycle (e.g. Rb, p53) (Vineis et al. 2010). In the case
of germline p53 (Li-Fraumeni syndrome) and Rb1 (Retinoblastoma) mutation carriers,
malignancy is the defining characteristic of the hereditary syndrome. In other cases, such
as APC (Familial Adenomatous Polyposis) and Nf1 (Neurofibromatosis Type I) mutation
carriers, afflicted individuals are not just at an increased risk for malignancy, but also
present with non-cancerous features and congenital anomalies.
1.2 Neurofibromatosis Type I (NF1)
Neurofibromatosis Type I, formerly known as von Recklinghausen disease, is one
of the most common heritable genetic conditions of the nervous system with a birth
incidence of 1 in 2500-3000 individuals (Friedman 1999). The NF1 disease is caused by
mutations in the neurofibromin I (Nf1) gene. Nf1 is a TSG due to its well-characterized
RAS-GRD, which negatively regulates RAS activity by accelerating the hydrolysis of the
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activated GTP-bound RAS (Xu et al. 1990). Therefore loss of NF1 activity leads to
activation of the wild-type Ras proto-oncogenes. NF1 is an autosomal dominant condition
with nearly complete penetrance of the associated phenotypes (Friedman 1999).
However, these traits are extremely variable in expression. Heterozygosity of the Nf1
gene leads to a wide variety of clinical pathologies including café-au-lait macules, axillary
freckling, Lisch nodules, cognitive disorders, bone deformities such as osseous lesions,
and neurofibromas. (Brems et al. 2009).

Presence of two or more of these

aforementioned benign clinical features encompasses the diagnostic criteria for the NF1
disease (Hirbe & Gutmann 2014). NF1 patients are also susceptible to various forms of
cancers, development of which requires a complete loss of Nf1 gene function (Roma
2001). NF1 patients are at risk for developing glioma of the optic pathway (15-20%),
MPNSTs (8-13%), gastrointestinal stromal tumors (4-25%), rhabdomyosarcomas (1.46%), leukemia, breast cancers, and other brain tumors (Hirbe & Gutmann 2014). Cancer
subtypes among NF1 patients exhibit severe pathology with poor prognosis. NF1 patients
have a five-fold increased chance of breast cancer occurring at a younger age (Sharif et
al. 2007; Wang et al. 2012), and the mortality rate for breast cancer in NF1 patients is
higher compared to the general population (Evans et al. 2011). NF1 patients also have
a five-fold increased chance of developing glioblastomas with poor prognosis (Hatori et
al. 2006; Gutmann et al. 2002).
Café au lait spots and multiple neurofibromas are distinguishing features of NF1
patients, as over 90% of NF1 patients display either one or both of these symptoms
(Compston 1994a; Huson 1989a). Neurofibromas mostly occur during adulthood in NF1
patients, however early onset of optic gliomas, plexiform neurofibromas, cognitive
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defects, and other neurologic syndromes have been reported in many cases (Watson
1967). Neurofibromas are complex benign peripheral nerve sheath tumors composed of
Schwann cells, fibroblasts, perineural cells, and mast cells (Rutkowski et al. 2000).
Cutaneous neurofibromas grow along the nerves or underneath the skin and are largely
asymptomatic (Gerber et al. 2009). Approximately 56-57% of all NF1 patients develop
plexiform neurofibromas which are extensive, larger neurofibromas that can occur
anywhere within the body (Kluwe et al. 1999; Mautner et al. 2008).

Plexiform

neurofibromas are thought to be congenital lesions that manifest themselves during
childhood in NF1 patients

(Nguyen et al. 2011).

Most importantly, plexiform

neurofibromas are painful lesions that can transform into the most aggressive cancer
subtype seen in NF1 patients called malignant peripheral nerve sheath tumors.
1.3 Malignant Peripheral Nerve Sheath Tumors (MPNSTs)
MPNST is a spindle cell soft-tissue sarcoma, which generally occurs on peripheral
nerves in the trunk, extremities and head and neck regions (Nikumbh et al. 2013).
MPNST is a rare form of cancer with a prevalence of 0.001% in the general population
(Ducatman 1986a). The lifetime risk for NF1 patients to develop MPNSTs is estimated
at 8-13% (Anghileri et al. 2006), with a recent study documenting the risk at precisely
11.7% in the NF1 population (Evans et al. 2012). In a Kaplan-Meier analysis, the fiveyear survival rate from diagnosis for MPNST patients with hereditary NF1 disease was
21%, compared to 42% for sporadic cases of MPNSTs (Evans et al. 2002). The majority
of hereditary MPNST cases occur in the adult population between 20-40 years of age
(Ducatman 1986b; Widemann 2009), however, MPNST is one of the more frequent soft-
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tissue sarcomas seen in the pediatric population with a higher incidence among the 1020 years age group (Bates et al. 2014).
Approximately 50% of MPNST cases occur in patients with NF1 disease (King et
al. 2000), and 41% of the remaining sporadic MPNST cases present with sporadic
mutations in the Nf1 gene (Bottillo et al. 2009). Interestingly, a retrospective study of the
northwest regional genetic registry in England reported a significant correlation between
p53 mutation carriers (Li Fraumeni Syndrome patients) and an increased risk of MPNST
development (Anghileri et al. 2006). This is surprising because mutations of p53 are not
commonly found in NF1-related MPNSTs. In one study, only 11% of MPNST cases
presented with mutations in p53; however, presence of these mutations was significantly
associated with high tumor grades (Holtkamp et al. 2007).
1.4 Role of NF1 in MPNSTs
Mutations of the Nf1 gene play a critical role in MPNST development given that the
majority (~70.5%) of MPNST cases harbor either germline or sporadic mutations in the
Nf1 gene (Bottillo et al. 2009). Various types of mutations including nonsense mutations,
missense mutations, intronic mutations, deletions and insertions occur in the Nf1 gene,
however no clear correlation between the specific type of mutations and their effects
(genotype-phenotype relationships) have been identified (Shen et al. 1996). 80% of Nf1
mutations in hereditary NF1 patients are frameshift or nonsense mutations, which result
in a non-functional truncated protein (Jett & Friedman 2010). Microdeletions of the Nf1
gene, specifically 1.5Mb deletions, confer increased risk of MPNST development in NF1
patients (De Raedt et al. 2003). Additionally, carriers of Nf1 microdeletions present with
severe cognitive dysfunction, early onset neurofibromas, and poor prognosis for MPNSTs
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(Shen et al. 1996; De Raedt et al. 2003). The Nf1 locus is the most highly mutable locus
in the genome with a rate of mutation 100-fold greater than the average mutation rate
(Shen et al. 1996). This is further supported by the fact that approximately half of NF1
individuals present with de novo mutations in the Nf1 gene not found in their parents
(Hirbe & Gutmann 2014).
1.5 Role of microenvironment in NF1-related malignancies
In-vivo disease modeling of Nf1-related tumors in genetically engineered mice has
emphasized the role of Nf1-heterozygous tumor microenvironment and other molecular
pathways (Munchhof et al. 2006). Complete deletion of the Nf1 gene in mice results in
embryonic lethality, whereas Nf1(+/-) mice do not develop neurofibromas or optic gliomas
classically associated with NF1 disease (Jacks et al. 1994).

Heterozygosity of the

microenvironment of Nf1(-/-) Schwann cells or other cells of cancer origin has been
identified as a requirement for development of optic gliomas as well as plexiform
neurofibromas in mice (Bajenaru et al. 2002; Zhu et al. 2002). The in vivo neurofibroma
model required tissue-specific deletion of Nf1 in Schwann cells using the Cre/Lox
transgene system, leaving intact the heterozygous state of the surrounding neurons,
fibroblasts and mast cells (Zhu et al. 2002). Nf1(+/-) microglia and mast cells are identified
as key players in development and maintenance of Nf1-related tumors (Daginakatte &
Gutmann 2007; Riccardi 1993). A serum biomarker study showed increased expression
of inflammatory cytokines such as IFN-γ, TNF-α, IL-6 and EGFR in patients with plexiform
neurofibromas or MPNSTs (Park et al. 2013), emphasizing the role of the Nf1(+/-)
heterozygous microenvironment particularly mast cells and monocytes in tumorigenesis.
Interestingly, the neurofibroma mice models do not develop MPNSTs. The development
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of an in vivo disease model of MPNST required haploinsufficiency of both Nf1 and p53,
in cis orientation on chromosome 11 (Cichowski et al. 1999).
1.6 Neurofibromin (Nf1) gene and function
The Nf1 gene is located on chromosome 17q11.2 encoding an ~280kD
cytoplasmic protein (Gutmann et al. 1995). The Nf1 gene is composed of 60 exons
covering over 350 kb of genomic DNA (Li et al. 1995), which results in a protein of 2818
amino acids (Bernards et al. 1992; Takahashi et al. 1994). Four alternative transcripts of
Nf1 have been identified called GRD I, GRD II, 3’ALT, and 5’ALT (Gutmann et al. 1995).
The NF1 protein is highly conserved with more than 98% homology between human and
mouse amino acid sequences (Bernards et al. 1993).

NF1 protein is found in the

cytoplasm where it co-localizes with cytoplasmic microtubules (Gregory et al. 1993).
Although NF1 is ubiquitously expressed in a variety of tissues and cell types, functional
studies indicate that NF1 is highly expressed in neurons, glial cells, Schwann cells, and
oligodendrocytes (Daston & Ratner 1992).
The NF1 protein contains several domains in addition to the RAS-GRD, which is
the most extensively studied domain of NF1. Protein-ligand interactions have been
reported in the PH-like domain (PH), Sec-14 domain (Sec), tubulin binding domain (TUB),
cysteine and serine rich domain (CSRD), and Syndecan binding region (SYN) of NF1
[Fig. 1.1] (S. Welti, 2008). NF1 forms a complex with CASK and syndecan via its SYN
domain in vivo (Hsueh et al. 2001). Yeast two-hybrid system studies have shown that
NF1 binds caveolin 1, a protein that regulates p21ras, PKC and growth response factors
(Boyanapalli et al. 2006). NF1 also regulates adenyl-cyclase activity in the ATP-PKAcAMP pathway in astrocytes (Tong et al. 2002; Dasgupta et al. 2003).
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The most well-studied functional domain of NF1 is the RAS-GRD encoded by exon
21 to 27a, which shares sequence homology with the p120GAP (Daston & Ratner 1992).
Increased RAS activity has been reported in NF1 patient-derived MPNST cells (Mattingly
et al. 2006) as well as mouse models. Results from an NF1 patient screen demonstrated
that a missense mutation, R1276P, in Nf1 RAS-GRD leads to an 8000-fold loss of the
GAP activity of NF1-GRD which can induce most NF1-related pathologies including
malignant Schwannomas (Klose et al. 1998). Furthermore, overexpression of Nf1 RASGRD restores cellular growth, proliferation and signaling in Nf1(-/-) cells (Hiatt et al. 2001).
These reports highlight the importance of NF1 as a tumor suppressor, which inhibits
cellular transformation by attenuation of Ras signaling and subsequent downstream
effector pathways.
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Figure 1.1: Domains of Neurofibromin I (NF1). Diagram of the prominent domains of
NF1. The GRD highlighted in blue is the RAS GAP-related domain of NF1, which shares
sequence homology to the p120-GAP protein. The GRD domain is flanked by a tubulin
binding region (Tub) in grey, Sec-14 domain (Sec) in purple, and a Ph-like domain (PH)
in red. NF1 protein also contains a cysteine/serine rich domain (CSRD) in grey, which
contains a number of cAMP-dependent PKA binding sites. Blue circles indicate
phosphorylation sites for PKA and yellow circles for PKC-α. Positions of missense
mutations are marked by red circles. Figure adapted from Neurofibromatoses (S. Welti,
2008).
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1.7 Signaling pathways regulated by NF1
1.7.1 Ras pathway
A proposed model of the underlying biological mechanism of Nf1-related MPNSTs
suggests that de-differentiation of Schwann cells is driven by the Ras pathway, via
activation of the MEK1/2-ERK1/2 axis (Harrisingh et al. 2004). NF1 inactivates Ras,
thereby promoting the differentiation of Schwann cells.

This hypothesis is further

supported by the Nf1 mouse model where Parada and colleagues demonstrated that the
congenital lesions of plexiform neurofibromas occur during a short stage in Schwann cell
development when immature and precursor cells, which are de-differentiated, are most
abundant (Le et al. 2011). It logically follows that in the absence of NF1, Ras pathway is
constitutively active, maintaining Schwann cells in a pre-mature stem like state. This stem
cell-like state of cancer cells is distinctively associated with poorly differentiated,
aggressive tumor sub-types (Monteiro & Fodde 2015). NF1 also plays an important role
during self-renewal of neuroglial progenitor cells and differentiation of astrocytes in the
peripheral nervous system (Hegedus et al. 2007). Spyra et al. have shown that an
established MPNST cell line, S462, expresses stem cell markers and characteristics of
stem-like cells such as self-renewal, clonality and an increased rate of tumor formation in
vivo (Spyra et al. 2011).
Given the critical role of Nf1-RAS GRD in development of NF1-related phenotypes,
including MPNSTs, members of the Ras pathway have been significant targets in
treatment of MPNSTs. There are 4 forms of the RAS protein: H-RAS, N-RAS, K-RAS A
and B, with N-RAS constitutively activated in Nf1-null MPNST cell lines (Mattingly et al.
2006). Members of the Ras protein family are mutated in over 30% of cancers, where
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they are involved in cellular transformation, proliferation, survival, growth and metastases
(Midgley & Kerr 2002). The Ras pathway is activated upon binding of growth factor
ligands (e.g. PDGF, EGF, etc.), which stimulate signaling cascades leading to recruitment
of guanine nucleotide exchange factors (GEFs).

Prenylation, a post-translational

modification, of the RAS protein facilitates its attachment to inner cell membrane where
GEFs allow exchange of Ras-GDP (inactive state) with pools of intracellular GTP, thereby
activating the Ras pathway (Basso et al. 2006; Gilman 1987). The Ras pathway is
inactivated when Ras-GTP is hydrolyzed to Ras-GDP by an intrinsic Ras-GTPase. The
hydrolytic activity of the intrinsic Ras-GTPase is weak, therefore inactivation of the Ras
pathway requires binding of extrinsic GAPs, such as the one encoded by Nf1, to
accelerate hydrolysis and inactivate Ras (Leondaritis et al. 2009). In absence of NF1,
constitutively active GTP-bound Ras activates several downstream signaling pathways.
1.7.2 RAF-MEK-ERK and PI3K-AKT-MTOR axis
Ras exerts its diverse array of effects through activation of two prominent
downstream effector pathways: rapidly accelerated fibrosarcoma (RAF)-Mitogen
activated protein/extracellular signal-regulated kinase (ERK) kinase (MEK)-ERK (RAFMEK1/2-ERK1/2) pathway and Phosphoinositide 3 kinase-mouse strain AK thymomamechanistic target of rapamycin (PI3K-AKT-mTOR) pathway [Fig. 1.2].

Both these

signaling pathways regulated by RAS are hyperactivated in various forms of cancers,
specifically those with aberrant RAS signaling.

Active MEK1/2-ERK1/2 signaling

promotes cellular proliferation and survival via regulation of cell cycle genes such as
cyclin D1, pRB, and CDK4 (Samatar & Poulikakos 2014). The significance of the RAFMEK1/2-ERK1/2 is well documented in proliferation and survival of NF1-associated
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MPNST cell lines (Mattingly et al. 2006). The activation of MEK1/2 occurs in 91% of
MPNST patient tissue samples, as compared to 21% of benign neurofibromas (Zou et al.
2009).
The induction of RAS also activates the PI3K/AKT/mTOR axis. Phosphatase and
tensin homolog (PTEN), the master negative regulator of PI3K/AKT/mTOR axis, is
frequently methylated in MPNST cell lines leading to increased AKT signaling in these
cells (Bradtmoller et al. 2012). Nf1 via its RAS-GRD negatively regulates the PI3K-AKTmTOR axis (Johannessen et al. 2005). The pathogenic role of PI3K/AKT/mTOR pathway
in MPNSTs is demonstrated by decreased cellular proliferation and angiogenesis in NF1associated MPNSTs upon inhibition of mTOR by rapamycin (Bhola et al. 2010). MEK1/2ERK1/2 and PI3K-AKT-mTOR signaling can be modulated independently of RAS by
extracellular ligands that bind the epidermal growth factor receptors (EGFR).
Accordingly, a recent study found that overexpression of EGFR via Janus kinase 2/signal
transducer and activator of transcription 3 (JNK2/STAT3) activation transformed
neurofibromas into MPNSTs in genetically engineered mice models (Wu et al. 2014).
These molecular pathways have been the main focus of targeted therapies in NF1-related
plexiform neurofibromas and MPNSTs; however, these therapies have exhibited limited
clinical success.
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Figure 1.2: Prominent NF1-related RAS-associated signaling pathways. Simplified
schematic of the NF1-related RAS-associated signaling axis. NF1 via its GRD attenuates
Ras signaling. Upon Nf1 deficiency, RAS bound by GTP is constitutively activated leading
to activation of downstream signaling cascades, notably RAF-MEK1/2-ERK1/2, and
PI3K-AKT-mTOR pathways. These pathways can be independently regulated by tumor
suppressors such as PTEN, which is often methylated in MPNSTs. Activation of the RAFMEK1/2-ERK1/2 and PI3K-AKT-mTOR signaling induces increased growth, proliferation
and survival of MPNSTs.
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1.7.3 RAS-independent pathways in NF1-related malignancies
Several studies have documented the role for NF1 as a tumor suppressor,
independent of its RAS-GRD. The importance of NF1 domains other than the RAS GRD,
is demonstrated by the failure to rescue embryonic lethality of Nf1(-/-) mice by induced
expression of the GRD. Even though over-expression of Nf1- RAS GRD rescued midgestation lethality in Nf1(-/-) mice, it did not restore aberrant neural crest tissue
development resulting in death (Ismat et al. 2006). NF1 has been shown to have effects
independent of its regulation of RAS in Nf1(-/-) Drosophilia melanogaster where Ras
signaling is intact and aberrant cyclic AMP dependent protein kinase A signaling is
responsible for reduced larvae and adult body size (Guo et al. 1997).
In fibrosarcoma cell lines, NF1 regulates the Rho-ROCK-LIMK2 pathway
independent of RAS effector pathways, to induce cytoskeletal reorganization (Ozawa et
al. 2005). A deficiency in the RAS-related protein R-RAS2/TC21 in Nf1(-/-) Schwann cells
results in up-regulation of TGF-β, leading to an increase in brain tumors and sarcomas
while decreasing neurofibromas (Patmore et al. 2012).

Moreover, gene expression

profiling of MPNST patient samples revealed a positive correlation between the activation
of the canonical Wingless/int (Wnt) signaling and malignancy of MPNSTs; in addition,
subsequent downregulation of Wnt signaling reduced cell viability and tumorigenic
potential in MPNST cell lines (Watson et al. 2013). Finally, by using the sleeping beauty
transposon based somatic mutagenesis system in mice models, a recent study identified
several new proto-oncogenes and tumor suppressors: FOXR2, PTEN, STAG1, TAOK1,
BMPR2, etc. that cooperate with the classical Ras-associated pathways in formation of
MPNSTs (Rahrmann et al. 2013).
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1.8 Clinical management of MPNSTs
Surgery is the major curative option for MPNSTs, however it is performed with wide
margins due to the size and location of these tumors (Friedman 2002). Even with surgery,
radiation therapy, and adjuvant chemotherapy, survival for NF1 patients with MPNSTs is
relatively poor. The poor prognosis of patients with hereditary NF1-related MPNSTs
appears to be correlated with the presence of Nf1 microdeletions which are associated
with increased severity of any NF1-related phenotype (De Raedt et al. 2003). Another
analysis suggests that poor survival of MPNST patients with NF1 is due to the size of
tumors that are bulkier in NF1 patients compared to those with a sporadic MPNST
(Anghileri et al. 2006). Concomitantly, large tumor size at presentation (typically >5 cm)
has been the most consistent adverse prognostic factor for MPNST patients (Zou et al.
2009; LaFemina et al. 2013). A meta-analysis of the effect of NF1 status on survival of
patients with MPNSTs shows a higher odds ratio of survival within the non-NF1 group
compared to the NF1 group, however within the last decade survival between the two
groups seems to have converged (Kolberg et al. 2013).
Chemotherapy for NF1 patients is primarily used in cases of unresectable
plexiform neurofibromas or metastatic disease such as MPNSTs (Kolberg et al. 2013).
Doxorubicin and ifosfamide have traditionally been used as the chemotherapy regimen
for MPNSTs (Zehou et al. 2013). However, a ten-year institutional review of treatment of
MPNSTs with doxorubicin and ifosfamide showed no correlation between chemotherapy
and patient survival, questioning the use of such chemotherapies in MPNST patients
(Zehou et al. 2013). In some cases, anthracycline is administered for palliative care in
MPNST patients (Kroep et al. 2011).
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Due to the failure of conventional chemotherapy, there has been a push towards
targeted therapy of specific molecular pathways involved in the biogenesis of NF1related MPNSTs. Based on the indispensable role of mast cells in MPNST
maintenance, pre-clinical studies targeting the tumor microenvironment of MPNSTs
have translated into human clinical trials using Gleevec, targeting c-kit function
[NCT02177825]. The most well-studied function of NF1 is attenuation of the
constitutively active Ras pathway in MPNSTs. Hence, inhibitors of the Ras pathway
and rapamycin analogues have been used to treat gliomas, MPNSTs and plexiform
neurofibromas, but with limited success. Tipifarnib, a farnesyl transferase inhibitor (FTI)
that blocks the prenylation step in activation of the RAS protein, failed Phase II clinical
trials [NCT00021541] in young NF1 patients with plexiform neurofibromas. It was
determined that geranylgeranyl transferase compensates for the inhibition of prenylation
of N-RAS and K-RAS by FTIs (Lerner et al. 1997; Whyte et al. 1997), suggesting that
the prenylation, membrane association, and transforming activity of N-RAS and K-RAS
was unaffected by the inhibition of farnesyl transferase. BRAF inhibitors, such as
sorafenib exhibited increased toxicity in NF1 patients in clinical trials (Kim et al. 2013),
whereas mTOR inhibitor sirolimus did not affect tumor burden, but prolonged time to
disease progression by four months in plexiform neurofibroma patients (Weiss et al.
2015).
Due to the failure of targeting RAS in patients with plexiform neurofibromas, new
strategies with re-designed agents targeting the downstream effectors of RAS pathway
are being employed. Selumetinib, an ATP-independent inhibitor of the MEK1/2 pathway,
was recently approved by the U.S. Food and Drug Administration (FDA) for the treatment
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of uveal melanomas. Over 80% of uveal melanomas harbor mutations in GNAQ or
GNA11, which behave similarly to BRAF mutations and result in constitutive activation of
the Mitogen-activated protein kinase (MAPK) pathway (Van Raamsdonk et al. 2010; Van
Raamsdonk et al. 2009). Also, selumetinib is currently in over twenty clinical trials for
various types of cancers, specifically those dependent on increased MAPK signaling. It
has proven patient tolerance in clinical trials, although, its effects as a single drug seem
to be limited (Adjei et al. 2008). Most importantly, therapeutic efficacy of selumetinib is
currently being investigated in PHASE II clinical trial for young adults with plexiform
neurofibromas [NCT02407405]. Due to the inherent complexity of NF1-related MPNSTs,
a single targeted agent therapy may not be efficacious, and therefore a combinatorial
approach that targets multiple disease related pathways is the obvious option for
comprehensive treatment and management of NF1-related MPNSTs. Targeting of Rasassociated pathways such as MEK1/2-ERK1/2 and PI3K-AKT-mTOR is necessary in
plexiform neurofibromas and MPNSTs as these pathways play an important role in tumor
development and maintenance.

Nonetheless, identification and targeting of Ras-

independent pathways is crucial for management of MPNSTs due to limited therapeutic
benefits associated with targeting Ras-dependent signaling.
1.9 The case for targeting BMP2-SMAD1/5/8 signaling in NF1-related MPNSTs
Our lab conducted a systematic gene expression profiling study using MPNST cell
lines with variable NF1 status to identify signaling cascades associated with NF1
malignancy, independent of the RAS-MEK1/2-ERK1/2 signaling, to identify new
druggable targets for MPNSTs. Using pathway specific intervention, BMP2 was identified
as a neurofibromin-dependent gene, independent of NRAS and MEK1/2 regulation (Sun
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et al. 2013). Functional significance of BMP2 in MPNSTs was supported by decreased
cellular migration and invasion upon inhibition of the BMP2 pathway in MPNST cell lines
(Sun et al. 2013). The role of BMP2 in progression to MPNSTs is evident by changes in
its expression levels at various stages of neurofibroma development in clinical specimens.
Bmp2 expression levels are significantly higher in MPNST patient samples, as compared
to the benign forms of neurofibromas [Fig. 1.3].
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Figure 1.3:
Bmp2 expression levels in various stages of NF1-related
Schwannomas. Data mined from a gene expression profiling study of Schwann cells
derived from neurofibroma patient samples (Miller et al. 2009). Low levels of Bmp2 are
detected in normal human Schwann cells (NHSC) as well as cutaneous neurofibromas:
dermal (dNFSC). Bmp2 levels in plexiform neurofibromas (pNFSC) are similar to those
in samples of dNFSCs, with a few outliers. MPNST patient samples show a remarkable
increase in relative Bmp2 expression levels. Analysis of Bmp2 expression in
neurofibroma patient samples suggests a stage-specific increase in Bmp2 levels, which
is associated with increased malignancy in NF1 patients (Sun et al. 2013).
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1.10 Bone Morphogenetic Protein 2 (BMP2)
Based on amino acid sequence homology, BMP2 belongs to the transforming
growth factor beta (TGF-β) family, which comprises the largest family of developmental
peptides (Wozney et al. 1988). The Bmp2 gene maps to chromosome 20p12, resulting
in a 396 amino acid glycosylated polypeptide (Rao et al. 1992). BMP2 is highly conserved
as mature regions of human, mouse and rat BMP2 are nearly identical (Chen et al.
2004a). BMP2 shares 98% amino acid sequence homology with BMP4, another member
of the TGF-β subfamily (Wozney et al. 1988). Homozygous Bmp2 mutant mice are nonviable, due to defects in development of exocoelomic cavity of the cardiac system (Zhang
& Bradley 1996).
BMPs signal via hetero-oligomeric complexes of serine/threonine kinase
receptors, type I and type II receptors. Specifically, BMP2 signals through three type I
receptors: BMPR-IA or ALK-3, BMPR-IB or ALK-6, and ActR-IA or ALK-2 (Koenig et al.
1994). Upon ligand binding, type I and type II receptors form a hetero-tetrameric receptor
complex (Moustakas et al. 2002) that initiates a signaling cascade involving Small
Mothers Against Decapentaplegic (SMAD) family of proteins [Fig. 1.4]. SMAD 1, 5 and 8
are phosphorylated by the BMP receptor complex, which then associate with SMAD4
(Chen et al. 2004b). The SMAD1/5/8-SMAD4 complex translocates to the nucleus and
initiates gene transcription in a tissue and developmental stage specific fashion
(Moustakas et al. 2002; Akhurst & Hata 2012).
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Figure 1.4: Signaling cascade of BMP and TGF-β pathway. TGF-β ligands such as
Activin, Nodal and TSP-1 signal through Type II receptors, whereas the BMP sub-family
signals via the Type I receptor. As BMPs bind Type I serine/threonine kinase receptors,
Type I receptors form a hetero-oligomeric complex with Type II receptors resulting in
phosphorylation of SMAD1/5/8. Phosphorylated SMAD1/5/8 associates with SMAD4,
which results in its translocation to the nucleus. Various transcription factors regulate the
nuclear SMAD1/5/8 complex to direct gene expression changes in cell differentiation,
migration, invasion, and metastasis in a tissue and context-dependent manner. Noggin
protein directly binds BMPs to inhibit their binding to the Type I receptor, whereas
SMAD6/7 negatively regulate phosphorylation, thereby activation of SMAD1/5/8. This
diagram is adapted from (Villapol et al. 2013)
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1.11 Biological functions of BMP2
BMPs are involved in regulation of growth, differentiation, motility, and apoptosis
in mesenchymal, epithelial, hematoepoetic, and neural cells during embryogenesis,
organogenesis, and tissue homeostasis (Chen et al. 2004a; Wu & Hill 2009). The BMP
sub-family has been extensively studied for its role in bone development and cartilage
formation. BMP2 induces chondrocyte and osteoblast pre-cursor formation by interacting
with the Sonic Hedgehog pathway during limb development (Niswander & Martin 1993).
Subcutaneous injections of recombinant BMP2 have been shown to induce periosteal
bone formation in mice (Chen et al. 2004a).

Due to its extensive role in bone

development, recombinant human BMP2 (rhBMP2) is administered to patients with
various forms of fractures, spinal fusions and other bone and cartilage related
abnormalities (Nauth et al. 2009). The use of rhBMP2 has been controversial based on
comparison of its therapeutic benefits versus side effects in clinical trials (Lubelski et al.
2015). Interestingly, one of the side effects associated with administering rhBMP2 is
tumor formation. A two year follow-up study of lumbar spinal arthrodesis patients who
received rhBMP2 with bone grafts showed a higher incidence (4.6%) of cancer
occurrence, as compared to the control group (0.8%), which only received bone grafts
(Carragee et al. 2013).
BMPs play multiple essential roles in development of the central and peripheral
nervous system.

BMP/SMAD signaling is repressed during neural induction and

development of the nervous system (Liu & Niswander 2005). BMP2 negatively regulates
maturation of oligodendrocytes, myelinating cells of the central nervous system, by
shifting neural precursors towards an astrocytic lineage (See et al. 2004).

BMP2
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cooperates with the Wnt signaling pathway to maintain pluripotency and suppress
differentiation of the neural crest stem cells (Kleber et al. 2005). Although BMPs promote
early glial development to immature Schwann cells from the neural crest (Dore et al.
2005), they prevent glial maturation by activation of AP-1 and Sp1 transcription factors
(TF), which regulate promoter activity of glial fibrillary acidic protein in the peripheral
nervous system (Dore et al. 2009).
1.12 Regulation of BMP2
1.12.1 Molecular inhibitors of BMP2/SMAD Signaling
Various members of the SMAD family negatively regulate BMP2 by binding its
receptors and inhibiting their function. SMAD6 binds type I receptors and prevents the
binding and phosphorylation of SMAD1/5/8 with SMAD4 (Imamura et al. 1997). SMAD6
is part of a negative feedback regulatory mechanism which is regulated by BMPs, given
that SMAD1 and SMAD5 binding sites have been identified in the promoter of SMAD6
(Ishida et al. 2000). Another prominent inhibitor of BMP2 signaling is Noggin, which
blocks the molecular epitope interfaces of both type I and type II BMP receptors (Krause
et al. 2011). Transgenic mouse models of Noggin develop osteoporosis with a significant
reduction in bone density, volume and formation (Devlin et al. 2003).
1.12.2 Transcriptional regulation of Bmp2
Mechanistic studies have demonstrated that Bmp2 is primarily regulated at the
transcriptional level. The promoter region of Bmp2 has two major transcription start sites
(TSS), with greater activity reported in the proximal promoter TSS as compared to the
distal promoter in osteoblasts (Ghosh-Choudhury et al. 2001; Helvering et al. 2000).
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Bmp2 is regulated by cis-regulatory elements with most enhancers located between 2.7
kb of the Bmp2 TSS; however, distant enhancer elements located as far as 153.7 kb of
the Bmp2 promoter have been shown to drive Bmp2 transcription in osteoblasts.
(Pregizer & Mortlock 2009; Chandler et al. 2007).
Multiple pathways converge to activate BMP2 signaling. Wnt/β-catenin pathway
controls Bmp2 transcription through the Tcf/Lef response elements in the Bmp2 promoter
(Zhang et al. 2013). Retinoic acid is a known inducer of BMP2 signaling which activates
BMP2 signaling via binding to retinoic acid response elements within the Bmp2 promoter
in osteoblasts and embryonic carcinoma cells (Rogers et al. 1992; Abrams et al. 2004).
Inflammatory cytokines such as NF-κB, TNF-α and IL-β regulate Bmp2 transcription in
chondrocytes and chondrosarcoma cell lines (Fukui et al. 2003; Feng et al. 2003). p53
and delta-NP63α in association with SMAD1/5/8 occupy promoters of BMP target genes,
such

as

inhibitor of

differentiation

(ID-1),

to

repress

epithelial-mesenchymal

transformation in mammary epithelial cells (Balboni et al. 2015). Bmp2 has also been
shown to be regulated at the post-transcriptional level by mRNA stabilization. Tumor
necrosis factor-alpha (TNF-α) stabilizes Bmp2 mRNA in rat chondrocytes via activation
of the p38 MAPK pathway (Fukui et al. 2006). These studies suggest that Bmp2 is
primarily regulated at the transcriptional level via TF-binding to promoter regions, and/or
through post-transcriptional mechanisms that modulate Bmp2 transcript stability.
1.13 Significance of BMP2 in tumorigenesis
Role of BMP2 in cancer development and maintenance is dependent on the
affected cell type and microenvironment. BMP2 is over-expressed in carcinomas of the
prostate, lung, colon, breast, and ovary (Dai et al. 2008; Katsuno et al. 2008; Bieniasz et
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al. 2015; Yu et al. 2008). BMP2 and BMP4 increase cellular motility and invasion in
prostate cancer cell lines in vitro and in vivo (Dai et al. 2008). However, the role of BMP2
in prostate and pancreatic cancer cells is dependent on the hormonal status of the cells,
where BMP2 stimulates tumor growth in androgen-independent prostate and pancreatic
cancer cell lines but represses tumor formation in androgen-dependent cell lines (Kleeff
et al. 1999; Ide et al. 1997). Moreover, BMP2 negatively regulates tumor growth in
myelomas (Hsu et al. 2005).

The role of BMP2 signaling in breast cancer is also

controversial. In MCF-7 breast cancer cells, over-expression of Bmp2 induced a G1
arrest and promoted apoptosis by increasing levels of cleaved caspase 3 (Chen et al.
2012). In contrast, inhibition of BMP2 by LDN-193189 reduced ALDH+ stem-like cells
and expression of mesenchymal markers inhibiting epithelial to mesenchymal transition
thus invasion, in mammary epithelial cells (Balboni et al. 2013).
BMP2 is over expressed in approximately 98% of lung carcinomas with little to no
expression in normal or benign lung tissue (Langenfeld et al. 2005). Serum levels of
BMP2 are two-fold higher in non-small cell lung cancer (NSCLC) patients as compared
to the controls, correlating with advanced clinical stage of disease (Fei et al. 2013). BMP2
promotes tumor proliferation in A549 NSCLC cells via activation of the canonical
SMAD1/5/8 pathway (Langenfeld et al. 2006), in which inhibition of BMP2 leads to
decreased cellular proliferation and migration (Chu et al. 2014).

A recent study

demonstrated that BMP2 in NSCLC cell lines is regulated by microRNAs (miRs). Induced
expression of miR-34b, miR-34c, and miR-486 attenuated BMP2 signaling and migration
and invasion in A549 cells (Fotinos et al. 2014). Similarly, over-expression of BMP2 in
epithelial ovarian cancers is well-documented where attachment and motility of epithelial
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ovarian cancer spheroids is regulated by increased expression of BMP2 via activation of
the AKT pathway (Peart et al. 2012). Increased Bmp2 mRNA levels in epithelial ovarian
cancer patient tissue samples positively correlate with tumor grade and shorter survival
(Le Page et al. 2009). There are conflicting reports on the role of BMP2 in glioblastoma
multiforme (GBM). One study reported that BMP2 is an effective pro-differentiation
treatment for GBM stem cells and sensitizes these cells to treatment with temozolamide
(Persano et al. 2012). On the contrary, Guo et al. showed that BMP2 promotes GBM
formation by increasing proliferation, migration, and self-renewal of GBM cancer stem
cells which can be reversed by overexpression of miR-656 (Guo et al. 2014).
1.14 Proposed role of BMP2 in development of NF1-related neurofibromas and
MPNSTs
By comparing conditional Nf1 knockout transgenic mouse models of premature
non-myelinating Schwann cells versus differentiated Schwann cells, Zheng et al.
identified Nf1 knockout premature Schwann cells as the cells of origin for plexiform
neurofibromas (Zheng et al. 2008).

This is in accordance with the neurofibroma

development model proposed by Harrisingh et al., in which the absence of NF1 and
constitutively active Ras pathway drives de-differentiation of Schwann cells to a premature state (Harrisingh et al. 2004), often marked by non-myelinated axons. Models of
plexiform neurofibroma and MPNSTs exhibit a premature stem cell-like Schwann cell
phenotype (Zheng et al. 2008; Spyra et al. 2011), and BMP2 is involved in maintenance
and differentiation of Schwann cell precursors during development. Exogenous addition
of BMP2 to rat Schwann cells inhibits expression of mature myelin-associated genes,
resulting in a phenotypic switch to a pre-myelinating, immature Schwann cell state (Dore
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et al. 2005). Many studies have reported cross-talk between BMP/TGF-β family members
and Wnt, Notch signaling pathways. These pathways maintain tumor stem cell niches
(Giancotti 2015) during development and tumorigenesis (Wu & Hill 2009; Guo & Wang
2009), and active Wnt signaling promotes the tumorigenic potential of MPNSTs (Watson
et al. 2013). These studies suggest a role for BMP2 in transforming neurofibromas to a
pre-mature stem-like state, which is characteristic of aggressive malignant tumors such
as MPNSTs.
One of the major questions in development of MPNSTs is the role of mutations at
loci other than the NF1 locus, such as p53, Rb, or PTEN. Only a fraction of NF1 patients
with plexiform neurofibromas develop MPNSTs, indicating that haploinsufficiency of NF1
is necessary, but not sufficient for tumor formation (Farid et al. 2014). Interestingly, the
mouse models of neurofibroma do not develop MPNSTs (Zhu et al. 2002), as
development of MPNST in vivo requires haploinsufficiency of both the Nf1 and p53 gene
(Cichowski et al. 1999). Given that carcinogenesis is a multi-step process, we expect
changes in multiple signaling pathways and cellular processes to govern the
transformation, development and maintenance of MPNSTs.

A retrospective

immunohistochemical staining of benign Schwannoma patient samples reported
increased staining of p16INK4A, indicative of senescence, which was absent in MPNST
patient samples (Simonetti et al. 2014). Furthermore, Nf1(+/-) melanocytes reprogrammed
to induced pluripotent stem cells senesce upon complete loss of Nf1 in vivo accompanied
by an up-regulation of p16INK4A (marker of senescence) and the senescence associated
secretory phenotype (Larribere et al. 2015). Ras-induced senescence is a well-studied
phenomenon where activation of oncogenic features driven by the Ras pathway are
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impeded by cellular defense mechanisms leading to senescence (Dimauro & David
2010).

Since NF1 deficiency leads to activation of the Ras oncogene, Ras-driven

senescence or tumor dormancy may be the major barrier in transformation of benign
neurofibromas to malignant MPNSTs. Thus, activation of tumorigenecity would require
mutations or aberrations in similar cellular defense signaling pathways particularly those
which regulate cell cycle such as p53, Rb, PTEN, etc. BMP2 is exclusively up-regulated
in MPNSTs as compared to benign neurofibromas (Miller et al. 2009), suggesting that
BMP2 may be one of the key players in transformation of a senescent or dormant state
of benign neurofibromas to a malignant phenotype. It is also possible that activation of
BMP2-SMAD1/5/8 may not trigger the tumorigenic switch but instead contribute to
transformation and/or maintenance of MPNSTs.
1.15 Project Overview
Using gene expression profiling, our lab identified BMP2 as the principal mediator
of TGF-β signaling in NF1-related MPNSTs, independent of NRAS and MEK1/2
regulation. Figure 1.5 shows the BMP/TGF-β pathway analysis of the gene expression
profiling study, in which BMP2 is the only significant member of the TGF-β family upregulated upon Nf1 knockdown in MPNST cell lines. Other BMP family members did not
exhibit significant changes in gene expression levels upon Nf1 knockdown, whereas
BMP4, the closest homolog of BMP2, was down-regulated.
The following chapters will address the role and significance of BMP2 in NF1related MPNSTs.

I will demonstrate the functional significance of targeting BMP2-

SMAD1/5/8 signaling in conjunction with MEK1/2 inhibition in MPNSTs. I will examine
the regulatory mechanisms that lead to activation of BMP2 upon knockdown of Nf1 to
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identify a specific genetic target for increased BMP2 signaling in MPNSTs. Overall, I will
present the feasibility of a combinatorial therapeutic approach by combined inhibition of
the BMP2 pathway with inhibitors of other relevant pathways, to provide a comprehensive
treatment strategy for improving clinical outcome of NF1-related MPNSTs.
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Figure 1.5: Pathway analysis of gene expression changes upon Nf1 knockdown in
MPNSTs. iPathway Guide software (Advaita Bioinformatics Co.) was used to analyze
gene expression changes in the dataset (Sun et al. 2013) comparing STS26T-V(Nf1+/-)
and STS26T-Nf1 KD cells. Genes highlighted in color exhibit at least a two-fold change
in expression levels with p-value<0.05. Red color denotes up-regulated genes and blue
denotes down-regulation. According to pathway analysis of gene expression changes
upon Nf1 knockdown in MPNST cell lines, BMP2 is significantly up-regulated, BMP4 is
down-regulated, whereas other BMPs do not change significantly. Other members of the
TGF-β subfamily such as TGF-β, Activin, TMBS1 are down-regulated. No significant
change is noted in Noggin, Chordin, or DAN (negative regulators of BMP2 signaling).
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CHAPTER II: Regulation of BMP2 by NF1 in MPNSTS
2.1 Summary
NF1 suppresses MPNST formation by regulating RAS-MEK1/2-ERK1/2 and PI3KAKT-MTOR signaling pathways, which are constitutively active upon NF1 deficiency and
play a pivotal role in tumor initiation and maintenance. Using gene expression profiling
of MPNST cell lines with variable NF1 status, our lab has identified that NF1 regulates an
important signaling axis of BMP2-SMAD1/5/8 in MPNSTs. We have shown that BMP2 is
up-regulated in Nf1(-/-) MPNST cell lines, and down-regulation of Nf1 results in increased
Bmp2 mRNA expression and subsequent activation of the SMAD1/5/8 pathway (Sun et
al. 2013). This chapter presents additional studies that validate the regulation of BMP2
by NF1 in novel MPNST cellular models. This chapter also serves as an introduction to
the patient-derived Nf1-null MPNST cell lines and Nf1 knockdown systems, which will be
used to study the therapeutic targeting and mechanistic regulation of BMP2 in MPNSTs
in the following chapters.
Data presented in this chapter establish that BMP2 is up-regulated upon NF1
deficiency at both transcript, protein, and secreted protein levels in MPNST cell lines.
BMP2 expression levels were determined in low passage patient-derived Nf1(-/-) MPNST
cells that are unaffected by artifacts of prolonged cell culturing, and better simulate the
physiological condition of MPNSTs in vivo as compared to the high passage cells used
previously. Furthermore, the regulation of BMP2 by NF1 is evaluated by using two
independent knockdown systems: stable lentiviral-mediated Nf1 knockdown and
conditional Nf1 knockdown.
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2.2 Materials and Methods
2.2.1 Cell culture and cell lines
All MPNST cell lines used in this study were maintained in RPMI 1640 medium
(Invitrogen, Waltham, MA, USA) supplemented with 5% fetal bovine serum (Hyclone
Laboratories, South Logan, UT, USA). Low passage human MPNST ST88-14(Nf1-/-), and
low passage T265(Nf1-/-) cells were a generous gift from Dr. Margaret Wallace
(Department of Molecular Genetics and Microbiology, University of Florida, FL, USA).
High passage human MPNST ST88-14(Nf1-/-) cells (from T. Glover, University of
Michigan, Ann Arbor, MI, USA), T265(Nf1-/-) cells (from G. De Vries, Hines VA Hospital,
Hines, IL, USA), and STS26T(Nf1+/-) cells (from D. Scoles, Cedars-Sinai Medical Center,
Los Angeles, CA, USA), were cultured for at least over 100 passages in our lab.
STS26T(Nf1+/-) cell line was used to establish a stable Nf1 knockdown cell line, and the
inducible Nf1 knockdown cell lines. Cell lines were periodically checked and found
negative for mycoplasma using MycoAlert Mycoplasma Detection Kit (Lonza, Basel,
Switzerland). Cultures were propagated for no more than 3 months at a time.
2.2.2

Lentivirus shRNA mediated stable Nf1 knockdown and inducible Nf1

knockdown system
The pGIPZ lentiviral Nf1 shRNA vector, Clone ID: V2LHS_76032 (Open
BioSystems, GE Dharmacon, Lafayette, CO, USA), was used for targeted knockdown of
Nf1 in the STS26T(Nf1+/) cell line. Nf1 shRNA and scrambled control lentiviral particles
were generated in HEK293T cells using a Trans-Lentiviral Packaging Kit (Thermo Fisher
Scientific, Waltham, MA, USA). STS26T(Nf1+/-) cells were infected with pGIPZ lentiviral
particles and selected with puromycin (1.0 µg/mL) for 8 days post-infection. Selected
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cells were confirmed by fluorescence microscopy for green fluorescence protein (GFP)
expression, and a pooled population was maintained in selection media containing
puromycin (0.5 µg/mL) for duration of experiments.
Conditional Nf1 knockdown cell lines were established using the parent Schwann
cell line STS26T(Nf1+/-).

STS26T was infected with two different clones of TRIPZ

inducible lentiviral Nf1 shRNA, Clone ID: V2THS_260806, and V3THS_380114 (GE
Dharmacon, Lafayette, CO, USA). Conditional Nf1 knockdown cells were selected with
and maintained in puromycin (0.25 µg/mL). Individual colonies were picked to generate
three stable tetracycline-regulated clonal cell lines. Selected clones were confirmed by
fluorescence microscopy for expression of red fluorescence protein (RFP) present on the
vector. Doxycycline (2 µg/mL) was added to cells to induce activation of the inducible
lentiviral Nf1 shRNA 24 hours prior to experiments.
2.2.3 Western blot analysis
Cells grown to 60-80% confluence were washed with cold PBS, scraped and lysed
with RIPA buffer (150 mM NaCl; 1% Triton X-100; 0.5% deoxycholic acid, 0.1% SDS; 50
mM Tris-Cl; pH 8.0) supplemented with 1% protease inhibitor cocktail, 1% PMSF (from
stock at 10 mg/mL in methanol), 1 mM Na3VO4, 1 mM Na4P2O7.10.H2O, and 1 mM NaF.
Eighty-five µg of whole cell lysate were loaded per well on 8% SDS polyacrylamide gel
electrophoresis (SDS-PAGE) for subsequent detection of neurofibromin. Sixty five µg of
whole cell lysate per well were run on 10% SDS-PAGE for subsequent detection of the
phosphorylated and total forms of SMAD1/5/8 and ERK1/2. α-Tubulin was used as the
loading control in all western blots. 0.45 µm nitrocellulose transfer membrane (Fisher
Scientific, Waltham, MA, USA) was used for protein transfer.
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Primary antibodies used in these experiments were rabbit polyclonal antineurofibromin 1:600 (#A300-140A, Bethyl laboratories, Montgomery, TX, USA), rabbit
monoclonal anti-phospho-SMAD1/5/8 1:600 (#9516S, Cell Signaling, Danvers, MA,
USA), mouse monoclonal anti-phospho-ERK1/2 1:1,000 (#9106S, Cell Signaling), rabbit
polyclonal anti-SMAD1/5/8 1:400 (#9106S, Cell Signaling), rabbit monoclonal antiERK1/2 1:1,000 (#4695S, Cell Signaling), and mouse monoclonal anti-α-tubulin 1:5000
(#T5168, Sigma-Aldrich, St. Louis, MO, USA). Secondary antibodies 1:10,000, were
conjugated to IRdye infrared dyes (Rockland Immunochemicals, Limerick, PA, USA).
Signal was detected using the Odyssey infrared imaging system and software (Licor
Biosciences, Lincoln, NE, USA) and the protein bands were quantified using ImageJ
software.
2.2.4 ELISA test for secreted BMP2 protein
Cell culture supernatants were collected 24 hours post-incubation in RPMI-1640
supplemented with 0.5% FBS. Conditioned media was collected and concentrated using
Amicon Ultra-4 Centrifugal filter units with 3 kDa cut-off (Merck Millipore, Billerica,
MA, USA). Secreted BMP2 levels were analyzed using the BMP2 Quantikine ELISA kit
(R&D Systems, Minneapolis, MN, USA). Duplicates of each sample were analyzed per
experiment. A standard curve was generated using optical density (O.D.) of the BMP2
standards provided by the vendor.

Secreted BMP2 levels for each sample were

calculated against the standard curve and normalized to the standard medium as well as
total protein concentration in conditioned media.
2.2.5 RNA extraction and quantitative real time PCR
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RNA was extracted from 100 mm plates of 70-85% confluent cells using the
RNeasy Mini Kit (#74106, Qiagen, Valencia, CA, USA). Three batches of total RNA (2.0
µg) for each cell line were reverse transcribed by SuperScript® II First-Strand Synthesis
System (Invitrogen, Waltham, MA, USA). Q-RT-PCR was performed using Power SYBR
Green MasterMix (Applied Biosystems, Carlsbad, CA, USA) and analyzed on the ABI
5700 Sequence Detection System (Applied Biosystems, Carlsbad, CA, USA). Primer
sequences for each gene analyzed are listed in Table 2.1. The relative fold change was
calculated using the CT method as follows: 2-ΔΔCT, where, ΔΔCT = (CT

Bmp2

- CT

Gapdh)

experiment - (CT Bmp2 - CT Gapdh) control.
Table 1: Primer sequences used for gene expression studies by qRT-PCR
Gene

Forward

Reverse

Bmp2

GACACTGAGACGCTGTTCC

CCATGGTCGACCTTTAGG

Gapdh ATCAAGAAGGTGGTGAAGCAG TGTCGCTGTTGAAGTCAGAGG

2.2.6 Statistical Analyses
All experiments presented were replicated a minimum of three times. Paired t-test or
ANOVA was used to determine the significant differences at 95% confidence interval.
2.3 Results
2.3.1 BMP2 is up-regulated in MPNSTs, independent of cell passaging effects
Our lab has previously demonstrated a significant increase in Bmp2 mRNA levels
in ST88-14(Nf1-/) and T265(Nf1-/-) MPNST cell lines as compared to normal human
Schwann cells (Nf1+/+) (Sun et al. 2013). However, the Nf1(-/-) MPNST cell lines used in
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the previous study had been cultured over many passages. Cells in culture are constantly
subjected to environmental and manipulative stresses, which may introduce genotypic
and phenotypic variations by selection of a dominant clone. These potential artifacts
introduced by prolonged cell culturing are well-documented in literature. For example,
PI3K-AKT signaling pathway inhibits activity of the androgen receptor in low passage
prostate cancer cells, however this effect is reversed in the high passages of the same
cell line (Lin et al. 2003). To circumvent the inherent bias of the cell culture system, low
passage (LP) patient-derived MPNST cells, passages:8-16 for LP ST88-14(Nf1-/-), and
passages:10-18 for LP T265 (Nf1-/-) cell lines are used in this study to validate the role of
BMP2 in MPNSTs. The results obtained from the LP (Nf1-/-) MPNST cells are presented
with those obtained from the high passages (HP) of the same (Nf1-/-) MPNST cell lines.
To assess the steady-state expression levels of Bmp2 mRNA in the LP Nf1-null
MPNST cells, RT-PCR for Bmp2 was performed using Gapdh as the housekeeping gene
[Fig 2.1]. Fold changes for the tested cell lines were normalized to Bmp2 expression
levels in the Nf1 heterozygous cell line: STS26T(Nf1+/-). Increased expression of Bmp2
mRNA is detected in the LP MPNST cells similar to the HP cells [Fig. 2.1]. Bmp2 mRNA
levels are higher in the ST88-14(Nf1-/-) cells as compared to the T265(Nf1-/-) cell lines,
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Figure 2.1: Quantitative RT-PCR of Bmp2 mRNA in MPNST cells. In Nf1-null MPNST
cells, the expression of Bmp2 is significantly higher than in the STS26T(Nf1+/-) cells, which
is used to calculate the relative fold change. RNA was extracted between passages 814 from LP ST88-14(Nf1-/-), passages 155-170 for HP ST88-14(Nf1-/-), passages 10-16
for LP T265(Nf1-/-) cells, and passages 208-230 for HP T265(Nf1-/-) cells. Data are
presented as mean of three independent experiments ± SD (*P<0.05, **P<0.01,
***P<0.001, n=3 compared with the STS26T(Nf1+/-), One-way ANOVA followed by
Tukey’s test for multiple comparisons).
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independent of passage numbers, however these differences are statistically
insignificant.
Next, the abundance of BMP2 protein was assessed by using phosphorylation of
SMAD1/5/8 as the readout in western blots in the low and high passage Nf1-null MPNST
cells. Upon binding of its receptor, BMP2 activates a signaling cascade leading to the
activation via phosphorylation of the SMAD1/5/8 complex.

Figure 2.2 shows that

phospho-SMAD1/5/8 is detected in all LP and HP ST88-14(Nf1-/-) cells. Analysis of low
and high passage T265(Nf1-/-) cells shows an active BMP2-SMAD1/5/8 pathway as well,
in which there is a slightly greater level of phospho-SMAD1/5/8 levels in the low passage
T265(Nf1-/-) cells as compared to its high passage counterpart.

The presence of

phospho-ERK1/2 in all of the tested cell lines is indicative of an active MEK1/2-ERK1/2
pathway, which is expected to be up-regulated in the absence of NF1 and subsequent
RAS activation. The Nf1-null status of these cell lines is confirmed in the western blot, as
no band for neurofibromin is detected in any of the cell lines [Fig 2.2].
The SMAD1/5/8 pathway can be activated by other members of the BMP subfamily such as BMP4, BMP7, BMP9, etc. As I used activation of SMAD1/5/8 as the
surrogate for BMP2 in western blots, the secretion of BMP2 was assessed to ensure that
the activation of SMAD1/5/8 is due to increases in BMP2 levels. This allows us to
delineate the activation of SMAD1/5/8 pathway by BMP2 from other BMP family
members. Furthermore, secretion of BMP2 is representative of its functional activity in
both LP and HP Nf1-null MPNST cells. By using the sandwich ELISA methodology,
conditioned media from each cell line was tested for levels of secreted BMP2 and
normalized to the medium control without cells.

Levels of secreted BMP2 in the
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conditioned media of each cell line are significantly higher compared to the control
medium [Fig 2.3]. LP and HP ST88-14(Nf1-/-) cells secrete between ~150-200 pg/mL of
BMP2. HP ST88-14(Nf1-/-) cells secrete significantly higher levels of BMP2 (~200 pg/mL)
as compared to the HP T265(Nf1-/-) cells (~100 pg/mL). Otherwise, differences in the
secretory concentration of BMP2 between low and high passage Nf1-null MPNST cell
lines is statistically insignificant. In summary, profiling of BMP2 mRNA, protein, and
secretion shows that BMP2 is expressed in Nf1-null MPNST cell lines, independent of
passage numbers. The data presented in this section has validated our previous findings
of BMP2 over expression in Nf1-null MPNSTs.
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Figure 2.2: Activation of SMAD1/5/8 and MEK1/2-ERK1/2 pathways in MPNST cells.
Representative western blot (n=3), of LP and HP (Nf1-/-) MPNST cells lines confirms the
NF1-null status of these cell lines as neurofibromin is not detected in any of the tested
cells. Activation of the BMP2-SMAD1/5/8 pathway via detection of phospho-SMAD1/5/8
shows an activated BMP2-SMAD1/5/8 signaling axis. The discrepancy of phosphoSMAD1/5/8 levels between low and high passage ST88-14 (Nf1-/-) cells can be explained
by reduced loading in the HP ST88-14(Nf1-/-) cells, as shown by the abundance of tubulin
used as the loading control. Phosphorylation of both ERK1 and ERK2 is detected in all
the cell lines, indicating an active RAS-MEK-ERK pathway.
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Figure 2.3: Secreted levels of BMP2 in NF1-null MPNST cells. Analysis of BMP2
secretion by ELISA using conditioned media from MPNST cell lines. BMP2 is secreted
in both low and high passage Nf1-MPNST cells. Accounting for standard deviation,
secreted levels of BMP2 vary minimally in both low and high passage ST88-14(Nf1-/-) cell
lines, with 150-200pg/mL of secreted BMP2, respectively. BMP2 secretion in HP ST8814(Nf1-/-) cells is significantly higher than in the HP T265(Nf1-/-) cells (P<0.01), however
the difference between secretion of BMP2 in the LP ST88-14(Nf1-/-) and LP T265(Nf1-/-)
is statistically insignificant . Cell culture supernatants from each cell line were collected
24 hours post-incubation in RPMI-1640 with 0.5% FBS, and plated in duplicates on to the
BMP2 ELISA plate. Secreted BMP2 levels for each sample were calculated against the
standard curve, and normalized for the medium, as well as total protein in conditioned
media. Data are presented as mean of three independent experiments ± SD (***P<0.001,
****P<0.0001, n=3 compared with the STS26T(Nf1+/-), One-way ANOVA followed by
Tukey’s test for multiple comparisons).
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2.3.2 BMP2 is regulated by NF1 in MPNST cells
We have established that BMP2 is overexpressed in Nf1-null MPNST cells,
independent of prolonged cell culturing effects. This sub-section will demonstrate that
the transcript and protein levels of BMP2 are dependent on the NF1 status in MPNST
cells. Results from our gene expression profiling study of a transient Nf1 knockdown in
MPNST cells validated by RT-PCR has shown a two-fold increase in the levels of Bmp2
mRNA upon knockdown of Nf1, which was followed by the activation of SMAD1/5/8
pathway (Sun et al. 2013). To validate the regulation of BMP2 by NF1, we generated two
novel Nf1 knockdown systems. The first approach was to generate a stable lentiviral Nf1
knockdown cell line from a sporadic MPNST cell line STS26T(Nf1+/-). To eliminate any
positional bias from the lentivirus site of chromatin integration, pooled populations of
infected cells were used.

The second approach was to generate an inducible Nf1

knockdown cell model, in which down-regulation of Nf1 can be temporally controlled in
the same cell population. The inducible Nf1 shRNA system provides the most specific
cellular model to study the precise effect of Nf1 on other signaling pathways by
circumventing any bias introduced by off-target effects of the Nf1 knockdown or control
shRNA constructs.

Moreover, by using multiple individual clones generated by the

inducible Nf1 knockdown shRNAs, the possibility of genotypic or phenotypic variations
among clonal cell lines or introduced by the site of lentiviral integration is minimized.
2.3.2.1 Increased BMP2 expression upon down-regulation of neurofibromin
STS26T(Nf1+/-), a sporadic MPNST cell line, was infected with either an Nf1
shRNA lentivirus to generate the STS26T-Nf1 KD cells, or a scrambled control to
generate the STS26T-V(Nf1+/-) cell line.

The lentiviral infection was confirmed by
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detection of the GFP-tag present on the plasmid vector by fluorescence microscopy. After
selection for eight days, pooled populations from both stably-infected cell cultures were
used. These cell cultures were propagated for maximum 6 weeks because at 8 weeks
or thereafter, presence of the NF1 protein was detected in the Nf1 knockdown cells. This
can be possibly due to methylation of the long terminal repeats (LTR) of the lentiviral
plasmid, or activation of a feedback mechanism by which Nf1 is re-activated in these cell
lines.
To validate the regulation of BMP2 by NF1, changes in the mRNA, protein, and
secretory levels of BMP2 were assessed between the STS26T-V(Nf1+/-) and STS26T-Nf1
KD cells. Bmp2 mRNA levels upon Nf1 KD were determined by calculating the fold
changes in Bmp2 levels relative to the STS26T-V(Nf1+/-) cell line [Fig. 2.4]. Bmp2 mRNA
levels increase approximately two-fold in the STS26T-Nf1 KD cells as compared to the
vector control, validating our previous findings based on the transient Nf1 knockdown
using miRNA oligonucleotides. RNA from HP ST88-14(Nf1-/-) cells was used as a positive
control.
Results from the western blot and its quantification revealed ~75% knockdown
efficiency of Nf1 in the STS26T-Nf1 KD cells [Fig. 2.5]. Although phospho-SMAD1/5/8 is
detected in the STS26T-V(Nf1+/-) cells, indicative of an active SMAD pathway, there is
increased phosphorylation of SMAD1/5/8 in the STS26T-Nf1 KD cells [Fig. 2.5(A)].
Quantification of the western blot shows that upon knockdown of Nf1, levels of
phosphorylated SMAD1/5/8 almost doubled in these cells [Fig. 2.5(B)]. As Nf1 negatively
regulates the Ras pathway, STS26T-Nf1 KD cells show a significant increase in the levels
of phospho-ERK1/2, indicative of activation of the MEK1/2-ERK1/2 axis of the Ras
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pathway. Analysis of BMP2 secretion by ELISA demonstrates that levels of secreted
BMP2 are dependent on the NF1 status [Fig. 2.6]. Approximately 90 pg/mL of BMP2 is
secreted upon knockdown of Nf1, whereas insignificant differences in BMP2 secretion
are noted between the vector control cells and the control media. Secreted levels of
BMP2 in the STS26-Nf1 KD cells are similar to those in the HP T265(Nf1-/-) cells at ~100
pg/mL [Fig 2.3]. Although phospho-SMAD1/5/8 is detected in the STS26T-V(Nf1+/-) cells
in Fig. 2.5, the absence of BMP2 secretion in the same cell line [Fig. 2.6] highlights that
NF1 exclusively regulates BMP2, independent of other BMP sub-family members, leading
to phosphorylation of SMAD1/5/8 complex in MPNST cells. Data collected from the
pooled Nf1 knockdown cells suggests that mRNA, protein, and secreted protein levels of
BMP2 are regulated by NF1, in which down-regulation of NF1 results in an increase in
BMP2 expression levels and activity.
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Figure 2.4: Bmp2 mRNA changes upon Nf1 knockdown. Upon knockdown of Nf1 in
the STS26T(Nf1+/-) cells, expression of Bmp2 increases two-fold as compared to the
vector control cell line. Fold changes were normalized to steady-state mRNA levels in
the STS26T-V(Nf1+/-) cells. ST88-14(Nf1-/-) cells were used as a positive control, where
Bmp2 expression was significantly higher than the expression in the sporadic MPNST
cells (P<0.001). Data are presented as mean of three independent experiments ± SD
(**P<0.01, ****P<0.0001, n=3 compared with the STS26T-V(Nf1+/-), One-way ANOVA
followed by Tukey’s test for multiple comparisons).
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Figure 2.5: Activation of BMP2-SMAD1/5/8 pathway is dependent on NF1 levels. A:
Representative western blot (n=3) shows that upon knockdown of Nf1 in the
STS26T(Nf1+/) cells, levels of phosphorylated SMAD1/5/8, indicative of BMP2 status, and
phospho-ERK1/2 increase. ST88-14 (Nf1-/-) cells were used as a positive control. n=3.
B: Quantification of the western blot shows that a knockdown efficiency of ~75% results
in an almost 200% increase in levels of phosphorylated SMAD1/5/8. Phosphorylated
ERK1/2 levels increase by ~220%. Paired t-test, n=3, *P<.05, **P<.01. Data presented
are mean quantification of 3 independent western blots ± SD.
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Figure 2.6: Secreted levels of BMP2 are regulated by NF1. Secreted levels of BMP2
are significantly higher from the STS26T-Nf1 KD cells, as compared to the STS26TV(Nf1+/-) cells. Approximately 90 pg/mL of BMP2 is secreted from the STS26T-Nf1 KD
cells, whereas insignificant differences in BMP2 secretion are noted between STS26TV(Nf1+/-) cells and the media control. Cell culture supernatants from each cell line were
collected 24 hours post-incubation in RPMI-1640 with 0.5% FBS, and plated in duplicates
onto an ELISA plate coated with the BMP2 antibody. Secreted BMP2 levels for each
sample were calculated against the standard curve, and normalized for the medium, as
well as total protein concentration in conditioned media. Paired t-test, n=3, **P<0.01.
Data are presented as the mean of three independent experiments ± SD.
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2.3.2.2 Changes in BMP2 levels are dependent on NF1 status in an inducible Nf1
knockdown system
To verify that changes in BMP2 expression are exclusively dependent on the NF1
status of MPNST cells, an inducible Nf1 knockdown system was chosen to study the
regulation of BMP2 by NF1 in the same cell population. The inducible Nf1 shRNA
constructs used in these experiments are driven by a tetracycline-responsive promoter,
in which Nf1 shRNA is activated by addition of doxycycline (dox), a more stable derivative
of tetracycline.

We employed two tetracycline-regulated Nf1 shRNA constructs as

described in the methods section to generate three inducible Nf1 KD cell lines. The
plasmid backbone for both vectors is the same with variable Nf1 shRNA sequences.
Conditional knockdown (Cond. KD) #2 and #3 were generated from the same inducible
Nf1 shRNA, whereas Cond. KD #1 was generated from a different Nf1 shRNA construct.
Between eight to thirteen colonies were picked from cells infected with each Nf1 shRNA
construct after selection for twelve days. After which, these colonies were expanded and
maintained in selection media.

Nf1 shRNA expression was induced by addition of

doxycycline (2 µg/mL) for 24 hours prior to assays. The inducible Nf1 shRNA vector
contains a RFP-tag which along with the Nf1 shRNA is driven by the tetracyclineresponsive promoter.

Hence, the presence of RFP expression is indicative of the

activated Nf1 shRNA. Based on RFP expression in dox-treated cells compared to the
untreated, three colonies were expanded and used for further experiments [Fig. 2.7].
Increasing the concentration of doxycycline did not affect levels of RFP expression in
these cells.
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+/-

STS26T(Nf1 ) infected with Tet-inducible Nf1 shRNA vector
Cond KD#1

Cond KD#2

Cond KD#3

Bright Phase

Turbo RFP

Figure 2.7: RFP expression in doxycycline-treated conditional Nf1 KD cells. Using
fluorescence microscopy, three clones generated from two inducible Nf1-shRNA
+/-

constructs infected in the STS26T(Nf1 ) cells were selected based on RFP expression
after 24 hours of treatment with doxycycline (2 µg/mL). Each clone is labeled as
conditional knockdown (Cond KD) followed by the clone number. The conditional
activation of the Nf1 shRNA is dependent on treatment with doxycycline. The nondoxycycline treated cells of these clones did not show any RFP expression (data not
shown). RFP was detected by the TRITC filter of the Olympus fluorescence microscope
with an excitation/emission wavelength of 488/532 nm, respectively.
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Changes in the mRNA levels of Bmp2 were determined by RT-PCR of the
untreated vs. the dox-treated conditional knockdown cells [Fig. 2.8]. As expected, levels
of Bmp2 mRNA increased upon induction of Nf1 shRNA by doxycycline, as compared to
the untreated controls. Levels of Bmp2 mRNA increase between ~1.6-1.85 fold in each
of the conditional KD cells, which is lower than the two-fold difference seen in the pooled
STS26T-Nf1 KD cells, as shown in Figure 2.1. Insignificant differences in Bmp2 mRNA
levels between the dox-treated STS26T(Nf1+/-) and untreated STS26T(Nf1+/-) cells
suggests that the increased Bmp2 mRNA levels in the dox-induced conditional Nf1
knockdown cells is not an off-target effect of doxycycline.
To evaluate changes in the protein abundance of activated SMAD1/5/8 complex
and ERK1/2 upon knockdown of Nf1 in the conditional KD cells, western blotting was
used [Fig 2.9]. First, we established that 2 µg/mL of doxycycline (concentration used to
induce the knockdown) does not affect phosphorylation of the SMAD1/5/8 complex [Fig
2.9(A)]. Fig 2.9(B) and (C) show that the induction of phospho-SMAD1/5/8 and phosphoERK1/2 are dependent on the status of NF1, following the same pattern as the pooled
stable Nf1 KD cells. Upon treatment with doxycycline for 18-24 hours, the efficiency of
Nf1 knockdown remained fairly consistent in multiple western blots with Cond KD #2 and
#3 displaying better knockdown efficiency as compared to Cond KD#1. Cond KD #2 and
#3 are clones picked from infected cells derived from infection of the same Nf1 shRNA
construct, suggesting that the efficiency of KD in the inducible system is dependent on
the specific shRNA construct.
In Figure 2.10, secretion of BMP2 was evaluated by ELISA from the conditional
KD cells. As shown by insignificant changes in secreted BMP2 levels between dox-
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treated STS26T(Nf1+/-) cells and untreated control, 2 µg/mL of doxycycline does not affect
secretion of BMP2. All conditional Nf1 KD cells showed an increase in the secreted levels
of BMP2 upon induction of the Nf1 shRNA in a span of 24 hours. In the conditional KD
cells, secreted BMP2 levels are dependent on the efficiency of KD as shown by the results
of western blotting in the same cell lines. Cond. KD#1 cells secrete lower levels of BMP2
as compared to the Cond. KD#2 and #3, which exhibit better Nf1 knockdown efficiency.
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Figure 2.8: Quantitative RT-PCR of Bmp2 mRNA in conditional Nf1 knockdown
cells. Upon treatment with doxycycline (2 µg/mL) for 24 hours, Bmp2 mRNA levels
increase between 160-185% in clones of the conditional Nf1 knockdown cells.
STS26T(Nf1+/-) cells treated with dox (2 µg/mL) were used as a negative control to
eliminate any dox-dependent changes in Bmp2 mRNA levels. Percent fold change for
each cell line were normalized to the untreated controls of each cell line which was set at
100%. Paired t-test, n=3, *P<0.05. Data are presented as the mean of three independent
experiments ± SD.
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Figure 2.9: BMP2-SMAD1/5/8 pathway is activated upon induction of Nf1 shRNA.
A: Treatment of STS26T(Nf1+/-) cells with various concentrations of doxycycline for 24
hours shows that 2 µg/mL doxycycline has no effect on the SMAD1/5/8 pathway. B:
Representative western blot (n=3) of the inducible Nf1 KD cells indicates that upon
treatment with 2 µg/mL doxycycline for 24 hours, levels of NF1 are downregulated
resulting in an increase in phospho-SMAD1/5/8 and phospho-ERK1/2 levels (n=3). C:
Quantification of protein bands was normalized to untreated cells. Results suggest a
proportional activation of p-SMAD1/5/8 and p-ERK1/2 based on the efficiency of KD of
Nf1. Data presented are mean quantification of 3 independent western blots ± SD
(*P<0.05, **P<0.01, ***P<0.001, ****P<0.0001, n=3, compared to the untreated controls
of each cell line, One-way ANOVA, followed by Tukey’s test for multiple comparisons).
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Figure 2.10: Secretion of BMP2 is regulated by NF1 in conditional Nf1-KD cells.
Evaluation of secreted BMP2 levels level upon induction of Nf1 shRNA. As shown by
insignificant changes in BMP2 secretion of the parent STS26T(Nf1+/-) cell line upon
treatment with doxycycline (2 µg/mL), dox does not affect secreted levels of BMP2. Upon
treatment with dox (2 µg/mL), secretion of BMP2 was induced in the conditional Nf1 KD
cells. Untreated control cells of conditional KD #1, #2, and #3 secrete little to none BMP2,
levels of which significantly increase upon induction of the Nf1 shRNA by treatment with
doxycycline. Cell culture supernatants from each cell line were collected 24 hours postincubation in RPMI-1640 with 0.5% FBS. Doxycycline (2 µg/mL) was added to the
indicated cells at the start of the 24-hr incubation period. Collected conditioned media
was plated in duplicate onto an ELISA plate coated with the BMP2 antibody. Secreted
BMP2 levels for each sample were calculated against the standard curve, and normalized
for the medium, as well as total protein concentration in conditioned media. Paired t-test,
n=3, **P<0.01. Data are presented as mean of three independent experiments ± SD.
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2.4 Conclusions
By using various MPNST cellular models and Nf1 knockdown systems, data
presented in this chapter have verified that NF1 regulates BMP2 expression in MPNST
cell lines. Specifically, down-regulation of NF1 results in increases in mRNA, protein, and
secreted levels of BMP2. Both low and high passage ST88-14(Nf1-/-) and T265(Nf1-/-)
cells exhibit increased levels of Bmp2 mRNA expression, active BMP2-SMAD1/5/8 and
MEK1/2-ERK1/2 pathways, and increased secretion of BMP2 as compared to the
STS26T Nf1(+/-) MPNST cells. Thereby, we can conclude that overexpression of BMP2
in MPNSTs is independent of cell culture passage effects. LP Nf1(-/-) MPNST cells were
chosen to validate BMP2 expression and activity as they are a better physiological model
of MPNSTs as compared to the HP Nf1(-/-) MPNST cell lines that were subjected to
prolonged cell culturing. Concomitantly, data obtained from the LP Nf1(-/-) MPNST cells
corroborates the gene expression profiling data of MPNST patient tissue samples by an
independent group in which BMP2 is exclusively up-regulated in MPNSTs as compared
to other benign forms of neurofibromas (Miller et al. 2009).
By using two independent Nf1 knockdown cellular models, we validated the
regulation of BMP2 by NF1, independent of genotypic variations that can be introduced
by off-target effects of shRNAs and sites of lentivirus insertion. Both the pooled Nf1 KD
cells and the doxycycline-inducible Nf1 KD cells have increased Bmp2 mRNA expression
and protein levels as compared to the control (Nf1+/-) cells. Data obtained from both the
pooled and the conditional Nf1 KD cells demonstrated that the activation of the BMP2SMAD pathway is dependent on the percentage of Nf1 knockdown. The greater the
decrease in NF1 levels, the higher the increase in levels of phosphorylated SMAD1/5/8
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and secreted levels of BMP2.

In summary, the increase in BMP2 expression and

subsequent activation of the SMAD pathway is dependent on NF1 status in MPNST cells.
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CHAPTER III: Therapeutic efficacy of combinatorial targeting of BMP2 and
MEK1/2 in MPNSTs
3.1 Summary
The clinical management of MPNSTs is quite challenging due to its aggressive
nature and limited therapeutic options. Surgical resection of the tumor with wide margins
is often insufficient to remove all tumors cells and necessitates the use of chemotherapy
to target the cancer cells left behind. Given that conventional chemotherapy has met with
limited success in the management of MPNSTs, targeted therapy of aberrant signaling
cascades involved in tumorigenesis is crucial for improving the clinical outcome of
MPNST patients. The goal of this chapter is to test novel therapeutic strategies to target
the viability, growth, proliferation, and invasiveness of MPNSTs by exploiting mechanisms
of signal transduction downstream of the NF1 deficiency. In doing so, we will explore the
functional significance of targeting BMP2 alone, and in combination with available
therapeutic options targeting the constitutively active RAS-MEK1/2-ERK1/2 pathway. To
determine the therapeutic efficacy of targeting of these signaling pathways in MPNSTs,
a small molecule inhibitor of the BMP2 type I receptor (LDN-193189) and a MEK1/2
inhibitor (Selumetinib) was employed. Data presented in this chapter are an evaluation
of the anti-cancer effects of mono-therapy or combinatorial therapy by these agents.
BMP2 is overexpressed in many different tumor types and has been associated
with motility, invasiveness, and metastasis (Singh & Morris 2010); all of which are defining
features of malignant spread of MPNSTs. Through inhibition of BMP2 signaling by LDN193189, our lab has previously shown that LDN-193189 reduces cellular motility and
invasiveness in various MPNST cell lines in vitro (Sun et al. 2013). Data presented in this
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chapter validate these effects in physiologically relevant cellular models. Additionally, we
demonstrate that selumetinib synergizes with LDN-193189 to decrease cellular viability,
whereas combination treatment with both the candidate agents does not affect cellular
migration and invasiveness of MPNST cells in comparison to treatment with LDN-193189.
3.2 Materials and Methods
3.2.1 Western blot analysis
MPNST cells were treated with specified concentrations of LDN-193189 and/or
AZD6244 or with vehicle control (DMSO) for indicated time points. These were washed
with ice cold PBS, scraped and lysed with RIPA buffer (150 mM NaCl; 1% Triton X-100;
0.5% deoxycholic acid, 0.1% SDS; 50 mM Tris-Cl; pH 8.0) supplemented with 1%
protease inhibitor cocktail, 1% PMSF (from stock at 10 mg/ml in methanol), 1 mM Na3VO4,
1 mM Na4P2O7.10H2O, and 1 mM NaF. Sixty-five µg of whole cell lysate was loaded per
well of 10% SDS-PAGE for subsequent detection of total and phosphorylated forms of
SMAD1/5/8 and ERK1/2.

α-Tubulin was used as the loading control.

0.45 µm

nitrocellulose transfer membrane (Fisher Scientific, Waltham, MA, USA) was used for
protein transfer.
Primary antibodies used in these experiments were rabbit monoclonal antiphospho-SMAD1/5/8 1:600 (#9516S, Cell Signaling, Danvers, MA, USA), mouse
monoclonal anti-phospho-ERK1/2 1:1000 (#9106S, Cell Signaling), rabbit polyclonal antiSMAD1/5/8 1:400 (#9106S, Cell Signaling), rabbit monoclonal anti-ERK1/2 1:1000
(#4695S, Cell Signaling) and mouse monoclonal anti-α-tubulin (#T5168, Sigma-Aldrich,
St. Louis, MO, USA). Secondary antibodies were conjugated to IRdye infrared dyes
(Rockland Immunochemicals, Limerick, PA, USA).

Signal was detected using the
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Odyssey infrared imaging system and software (Licor Biosciences, Lincoln, NE, USA)
and the protein bands were quantified using ImageJ software.
3.2.2 In vitro cytotoxicity assays
In vitro cytotoxicities of LDN-193189, and AZD6244, alone or in combination were
measured by using 3-[4,5-dimethyl-thiazol-2-yl]-2,5-diphenyltetrazolium-bromide (MTT)
(Sigma-Aldrich, St. Louis, MO, USA) in STS26T-V(Nf1+/-), STS26T-Nf1 KD, low and high
passage ST88-14(Nf1-/-), and low and high passage T265(Nf1-/-) cells. Briefly, 1500-3000
cells were added to a 96-well plate and cultured in the presence of increasing drug
concentrations for 48 hours. After 48 hours, MTT was added to a final concentration of 5
mg/mL. After four hours, formazan crystals were solubilized by addition of 0.1 N HCl in
anyhydrous isopropanol. Crystals were allowed to dissolve for 15 minutes with gentle
shaking, after which plates were read within an hour using a microplate reader at 570 nm,
with a background subtraction of 690 nm.

GI50 values were calculated as drug

concentrations necessary to inhibit 50% growth compared to untreated control cells using
GraphPad Prism 5 software (GraphPad Software, La Jolla, CA, USA). The anti-viability
interaction of LDN-193189 and AZD6244 was determined by standard isobologram
analyses and by evaluating combination index (CI) values, calculated using CompuSyn
software (ComboSyn Inc., Paramus, NJ, USA), where CI < 1, CI = 1, and CI > 1 indicate
synergistic, additive, and antagonistic effects, respectively.
3.2.3 Wound healing assay:
The effect of LDN-193189 and AZD6244 on motility was investigated by using
CytoSelect™ Wound Healing Assay Kit (Cell Biolabs, Inc., San Diego, CA, USA). Cells
were seeded at 4-5x104 cells/well in 24-well plates containing inserts aligned in the same
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direction and incubated for 24 hours to allow the cells to adhere. After 24 hours, inserts
were removed, and cells were washed twice with PBS to remove dead cells and debris.
Next, the cells were treated with indicated concentrations of LDN-193189 and AZD6244
for another 48 hours. To better quantify the cell migration images by fluorescence, low
and high passage T265(Nf1-/-) and ST88-14(Nf1-/-) cells were infected with the GFP
expressing lentiviral plasmid.

Migration into the wound field was determined by

fluorescent images focused on the center of the wound field, photographed by Olympus
IX71 fluorescent microscope, and area of the scratched region in pixels was quantified by
ImagePro Software (Media Cybernetics, Rockville, MD, USA).

This assay was

independently repeated at least three times per cell line.
3.2.4 In vitro cell invasion assay:
The effects of LDN-193189 and AZD6244 alone, or in combination on MPNST cell
invasion were determined using the CytoSelect™ 96-well cell invasion assay kit (Cell
Biolabs Inc., San Diego, CA, USA) containing polycarbonate membrane inserts (8 µm
pore size). Cells were pretreated overnight with indicated concentrations of LDN-193189,
AZD6244, alone or in combination before seeding to the chambers. The day of seeding,
the basement membrane layer was rehydrated by adding 100 µl of warm, serum-free
medium to the inner compartment and incubated for 1 h in a cell culture incubator. A 100
µl cell suspension (1 × 105 cells/ml) for each cell line in serum-free medium with/without
the indicated treatments was plated in duplicates on to the upper chamber wells
containing the basement membrane after removal of the rehydration media. FBS was
used at 10% as the chemoattractant of which 150 µl was added to the feeder tray.
Duplicate controls of each cell suspension were plated in upper chambers adjoining
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feeder wells without any chemoattractant. After 18 h of incubation, the medium in the
membrane chamber was transferred to a new harvesting tray containing 150 µl of
detachment solution for 30 min. The cells were dislodged completely from the underside
of the membrane by gently tilting the membrane several times. Fifty microliters of 4x lysis
buffer/CyQuant GR dye solution was added to all samples, which were then incubated
for 20 min at room temperature. One hundred and fifty microliters of the lysate was
transferred to a black walled plate with optical bottoms (Sigma-Aldrich, St. Louis, MO,
USA) and fluorescence measurements were performed in a fluorescence plate reader
Spectramax I3X (Molecular Devices, Sunnyvale, CA, USA) at 480 nm/520 nm. This
assay was independently repeated three times.
3.2.5 Statistical analyses and synergy calculations:
All experiments presented were replicated a minimum of three times. Paired t-test or
ANOVA was used to determine the significant differences at 95% confidence interval.
Drug/drug synergy was evaluated by the Chou combination index (CI) using Compusyn
software (http://www.combosyn.com). For these calculations, 8-point dose response
curves for LDN-193189 in combination with selumetinib were constructed. Bliss
Independence (BI) model was used to calculate the therapeutic interactions of the
combination of candidate agents on migration and invasion as follows:
BI = ((Fa+Fb)-(Fa x Fb))/Fab
where:
Fa = fraction of effect of drug A
Fb = fraction of effect of drug B
(Fa+Fb)-(Fa x Fb) = predicted sum of the effects of combination treatment
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Fab = actual effect of combination therapy found experimentally
3.3 Results
To investigate the therapeutic efficacy and significance of targeting BMP2SMAD1/5/8 alone and in combination with MEK1/2-ERK1/2 signaling, we evaluated the
effects on cell viability, migration and invasion of MPNST cells upon single and dual
targeting of the aforementioned pathways. First, we determined the optimal dose for
inhibition of the targeted pathways by the candidate agents. This was followed by a
comprehensive analysis of the effects on cell viability, migration and invasion of single
agent treatment versus combination treatment.

The experiments presented in the

following sections have been conducted in both low and high passage Nf1(-/-) MPNST cell
lines to minimize any cell line specific effects. Analysis of the data from the LP Nf1(-/-)
MPNST cells provides physiologically relevant assessment of the anti-tumor interactions
of the candidate agents.
3.3.1 LDN-193189 inhibits BMP2-SMAD1/5/8 signaling
BMP2 exerts its functional effects by binding to the BMP-activated Type I
receptors, which then form a complex with Type II receptors with serine threonine kinase
activity resulting in phosphorylation of SMAD1/5/8.

The phosphorylated form of

SMAD1/5/8 binds SMAD4 to translocate to the nucleus and thereby regulate gene
expression (Chen et al. 2004a).

To study the role of activated BMP2-SMAD1/5/8

signaling in MPNSTs, we utilized a small molecule inhibitor of BMP signaling, LDN183189 [Fig. 3.1(A)]. Upon binding to the Type I receptors, LDN-193189 suppresses the
hetero-oligomerization of the Type I and Type II serine/threonine kinase receptors leading
to the inhibition of phosphorylation of the SMAD1/5/8 complex (Vogt et al. 2011) [Fig

65

3.1(B)]. For BMP2, receptor oligomerization is the critical step dictating the initiation of
the SMAD1/5/8 signaling axis (Nohe et al. 2002). Thereby, inhibition of the BMP2SMAD1/5/8 signaling by inhibition of the ligand binding to the Type I receptors by LDN193189 allows us to investigate the therapeutic potential of targeting BMP2 in MPNSTs.
Currently, there are no FDA approved BMP2 receptor inhibitors. LDN-193189 is
the most specific BMP2 activated Type I receptor inhibitor. It has at least a 100-fold
selectivity for type I receptors (ALK2, ALK3 and ALK6) over other receptors of the TGFβ pathway (Engers et al. 2013). Results from animal studies demonstrate that LDN193189 is readily available in plasma after intraperitoneal injection or oral administration
with a plasma half-life of 1.6 – 4.3 hours depending on the mode of delivery (Hong & Yu
2009; Cuny et al. 2008). Most importantly, LDN-193189 administered at biochemically
relevant concentrations does not induce weight loss, growth retardation, skeletal,
hematopoietic or developmental abnormalities, when administered for more than two
months to newborn or adult mice (Yu et al. 2008).
We evaluated the inhibition efficacy of LDN-193189 at different concentrations and
time intervals in MPNST cells to optimize the drug application. We found that treatment
of ST88-14(Nf1-/-) cells with 0.01 μM LDN-193189 for 1 hour resulting in nearly complete
inhibition of phospho-SMAD1/5/8 [Fig. 3.1(C)]. Upon increasing concentrations of LDN193189 particularly 0.03 µM to 0.3 µM, total SMAD levels increase. We further evaluated
the effects of using LDN-193189 on the MEK1/2-ERK1/2 pathway. We did not find any
changes in the activation of ERK1/2 at 0.01 µM LDN-193189 or at a 30-fold higher
concentration of 0.3 µM LDN-193189. All MPNST cell lines used in the study exhibited
the same response to treatment with LDN-193189. From these data we concluded that
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a dosage between 0.01 µM and 0.3 µM of LDN193189 effectively inhibits BMP2 signaling
by preventing phosphorylation of SMAD1/5/8 without any effects on MEK1/2-ERK1/2
signaling in MPNST cells.
3.3.2 Selumetinib inhibits MEK1/2 signaling in MPNST cells
Kinases of the MAPK pathway are significant targets for cancer therapy. MEK1/2
phosphorylates ERK1/2 on the tyrosine and threonine residues in the activation loop
leading to promotion of cell survival, growth and proliferation [Fig. 3.2(B)]. Selumetinib is
a specific ATP-uncompetitive inhibitor of the MEK1/2 [Fig. 3.2(A)] which is in clinical trials
for various types of cancers specifically those that are dependent on increased MAPK
signaling. It was recently approved by the U.S. FDA for treatment of uveal melanomas,
in which GNAQ and GNA11 mutations drive the activation of the MAPK pathway (Van
Raamsdonk et al. 2010; Van Raamsdonk et al. 2009).

Selumetinib has also been

clinically evaluated as a single and a combinatorial drug in a variety of cancers including
melanoma, pancreatic, biliary tract, colorectal, and lung cancers (Haass et al. 2008;
Bennouna et al. 2011; Hainsworth et al. 2010; Bekaii-Saab et al. 2011). Most importantly,
selumetinib has proven patient tolerance in clinical trials, however, its effects as a single
drug seem to be limited (Adjei et al. 2008). Selumetinib is currently in Phase II clinical
trial for young adults with NF1 and inoperable plexiform neurofibromas [NCT02407405].
Preliminary data from the Phase I study on plexiform neurofibromas in NF1 patients
shows that selumetinib has a mean terminal plasma half-life of 7.6-7.7 hours, depending
on level of dosage in NF1 patients. Notably, all patients with >1 MRI restaging had a
median decrease of 24% in the volume of plexiform neurofibromas, with reversible
toxicities (Widemann et al., 2014).
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The chemical name of selumetinib is AZD6244, which is used in the figures of this
chapter. To test the efficacy of selumetinib, we treated MPNST cells with indicated
concentrations of selumetinib to optimize the drug application [Fig. 3.2(C)]. We found
that the treatment of ST88-14(Nf1-/-) cells with 0.03 μM selumetinib for 1 hour inhibits
phosphorylation of ERK1/2 nearly completely. We further evaluated the effect of using
0.03 μM selumetinib on the BMP2-SMAD1/5/8 pathway, in which we did not find any
changes in SMAD1/5/8 signaling dependent at the concentration of selumetinib up to
3.0µM. Dose response for selumetinib treatment was similar in all MPNST cell lines used
in this study.
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A

B

C

Figure 3.1: Efficacy of LDN-193189 in inhibiting BMP2-SMAD1/5/8 signaling. A:
The chemical structure of LDN-193189 (Engers et al. 2013). B: Schematic of the BMP2SMAD1/5/8 signaling pathway and inhibition by LDN-193189. C: Representative western
blot of titration of LDN-193189 in MPNST cells to determine optimal dose of inhibition.
LDN-193189 inhibits phospho-SMAD signaling at 0.003 µM and more efficiently at 0.01
µM, without any effects on the ERK signaling pathway in the ST88-14(Nf1-/- cells). Cells
were treated with the indicated concentrations for 1 hour and whole cell lysate was
fractionated on SDS-PAGE followed by immunoblotting for indicated proteins.
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B

C

Figure 3.2: Efficacy of selumetinib (AZD6244) in inhibition of MEK1/2-ERK1/2
signaling. A: The chemical structure of AZD6244 (Yeh et al. 2007). B: Schematic of the
AZD6244 inhibition of MEK1/2 leading to inhibition of ERK1/2. C: Representative western
blot of titration of AZD6244 in MPNST cells to determine optimal dose of inhibition.
AZD6244 inhibits phospho-ERK1/2 at 0.03 µM and continues to inhibit the MEK1/2ERK1/2 pathway without any effects on the SMAD1/5/8 pathways. Cells were treated with
the indicated concentrations for 1 hour and whole cell lysate was fractionated on SDSPAGE followed by immunoblotting for indicated proteins.
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3.3.3 Selumetinib synergizes with LDN-193189 to decrease viability of MPNST cells
In order to investigate the effects of BMP2 or MEK1/2 inhibition on cell viability in
MPNSTs, a standard 48-hour MTT assay was employed. Concentration ranges were
initially chosen based on results from the western blot analysis, corresponding with the
length of the MTT assay [Fig. 3.3]. LDN-193189 as a single agent has a cell viability GI50
range of ~1.0-2.0 µM as a single agent in various MPNST cell lines [Figs. 3.4(A), 3.5(A),
3.6(A)]. The GI50 of LDN-193189 at which it affects cellular viability is at least 10-fold
higher than the dose required to inhibit SMAD1/5/8 signaling in 48 hours as seen by
western blotting [Fig. 3.3(A)]. Therefore, the effects on cellular viability and proliferation
of MPNST cell lines by LDN-193189 are potentially off-target effects of a higher dose.
Next, we determined the cell viability GI50 of selumetinib in MPNST cell lines.
STS26T-V(Nf1+/) and STS26T-Nf1 KD cells have a cell viability GI50 of ~10 µM [Fig.
3.4(B)], HP ST88-14(Nf1-/-) and HP T265(Nf1-/-) cells have GI50s between 7-9 µM [Figs.
3.5(B), 3.6(B)], respectively.

LP ST88-14(Nf1-/-) and LP T265(Nf1-/-) cells are more

sensitive to selumetinib treatment with a cell viability GI50 range of ~3-4 µM as compared
to their HP counterparts [Figs. 3.5(B), 3.6(B)]. Interestingly, selumetinib also requires a
much higher concentration to affect cellular viability than the concentration required to
inhibit its target in 48 hours [Fig. 3.3]. The cell viability GI50s obtained for the single agent
treatments were used for determination of appropriate concentration ranges of these
agents in combinatorial cell viability studies.
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A

B

Figure 3.3: Analysis of inhibition of BMP2 by LDN-193189 and MEK1/2 by
selumetinib (AZD6244) upon 48 hours of drug treatments. A: LDN-193189 continues
to inhibit phospho-SMAD1/5/8 at the low concentration of 0.01 µM in 48 hours, however,
it requires between 0.03 and 0.1 µM for complete inhibition of the target in 48 hours. None
of the tested concentrations of LDN-193189 up to 1.0 µM had any effects on MEK1/2ERK1/2 signaling. Similar dose responses were obtained for all tested MPNST cell lines.
B: AZD6244 inhibits phospho-ERK1/2 in a concentration dependent manner, in which
increasing the concentration of the drug leads to a further decrease in phospho-ERK1/2
levels. Cells were treated with the indicated concentrations for 48 hours, and whole cell
lysate was fractionated on SDS-PAGE followed by immunoblotting for indicated proteins.
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After identification of the proper concentration range for each of the drugs on cell
viability, the effects of the combination of LDN-193189 and selumetinib were determined
by a 48 hour MTT assay. Standard isobolograms and combination indices (CIs) were
used to compare the combinatorial effects of both agents. Isobolograms take into account
the GI50 of each drug and allow for a quick evaluation of the nature of the drug interaction.
Each axis is representative of the concentration of the indicated drug. Any combination
that lies below the line connecting the points representing GI50s of single drug treatments
is considered to be synergistic, those on the line are considered additive, and those above
the line are considered antagonistic interactions.

We used four concentrations of

selumetinib ranging from 0.1 µM to 3.0 µM, based on the biochemically relevant inhibition
of the MEK1/2-ERK1/2 pathway at 48 hours, in combination with seven increasing doses
of LDN-193189 corresponding with its cell viability GI50 in each of the cell lines.
Selumetinib and LDN-193189 synergistically inhibited cell viability in the STS26T-V(Nf1+/) and STS26T-Nf1 KD cells with CI values ranging from 0.55-0.74 [Figs. 3.4(C) and (D)].
The combinatorial drug treatment has a strong to moderate synergistic effect on cell
viability in the HP ST88-14(Nf1-/-) cells [Fig. 3.5(D)]. While combinatorial treatment of HP
T265(Nf1-/-) cells trends towards additivity at low concentrations of selumetinib, it appears
to synergize at the higher doses [Fig 3.6(D)]. Dual treatment with LDN-193189 and
selumetinib show a strong synergistic interaction inhibiting cell viability of both LP ST8814(Nf1-/-) and T265(Nf1-/-) cells [Figs. 3.5(C), and 3.6(C)]. Table 3.1 displays the average
CI values obtained from combination treatments of the tested MPNST cell lines.
From the cell viability studies of LDN-193189 as a single agent or in combination
with selumetinib, we conclude that these drugs synergize to inhibit cellular viability in
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MPNST cells. The strongest synergistic interaction of both agents is seen in the low
passage MPNST cells with the combination of LDN-193189 and lower concentrations of
selumetinib.

However, the inhibitory effects on cell viability by LDN-193189 and

selumetinib are potentially off-target effects as the individual GI50s of the candidate agents
are higher than the effective dose at which these agents inhibit their targets.
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Figure 3.4: The combinatorial effects of LDN-193189 and selumetinib (AZD6244)
on cell viability in STS26T-V(Nf1+/-) and STS26T-Nf1 KD cells. A and B: The GI50s
for single agent treatments are plotted on a semi-logarithmic scale in which x-axis (log10
scale) indicates drug concentration and y-axis represents % effect on cell viability as
measured by 48-hour MTT assays. Data were analyzed by non-linear regression analysis
to generate sigmoidal dose response curves and each point represents mean value from
three independent experiments ± SD. A: The effects of single treatment by LDN-193189
on the percent of viable STS26T-V(Nf1+/-), GI50: 1.8 ± 0.2 and STS26T-Nf1 Kd cells, GI50:
2.1 ± 0.1. B: The effects of single treatment by AZD6244 on the percent of viable
STS26T-V, GI50: 9.8 ± 0.8, and STS26T-Nf1 KD cells, GI50: 10.2 ± 0.3. C and D: Standard
isobologram analyses of the interactions between LDN-193189 and AZD6244 on cell
viability. Each axis represents the GI50 concentration of the indicated drug. All drug
combinations in both cell lines show a synergistic effect. Data points represent the
average value from three independent experiments ± SD.
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Figure 3.5: The combinatorial effects of LDN-193189 and selumetinib (AZD6244)
on cell viability in low and high passage ST88-14(Nf1-/-) cells. A and B: The GI50s for
single agent treatments are plotted on a semi-logarithmic scale in which x-axis (log10
scale) indicates drug concentrations and y-axis represents % effect on cell viability as
measured by 48-hour MTT assays. Data were analyzed by non-linear regression analysis
to generate sigmoidal dose response curves, and point represents mean value from three
independent experiments ± SD. A: The effects of single treatment by LDN-193189 on
the percent of viable LP ST88-14(Nf1-/-), GI50: 1.3 ± 0.3 and HP ST88-14(Nf1-/-), GI50: 2.0
± 0.1. B: The effects of single treatment by AZD6244 on the percent of viable LP ST8814 (Nf1-/-), GI50: 2.7 ± 0.2, and HP ST88-14 (Nf1-/-), GI50: 7.6 ± 0.3. C and D: Standard
isobologram analyses of the interactions between LDN-193189 and AZD6244 on cell
viability. Each axis represents the indicated drug concentrations. All drug combinations
exhibit a synergistic effect in both low and high passage cells with increased synergy in
the LP ST88-14(Nf1-/-) cells. Data points represent the average value from three
independent experiments ± SD.
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Figure 3.6: The combinatorial effects on cell viability of LDN-193189 and
selumetinib (AZD6244) in low and high passage T265(Nf1-/-) cells. A and B: The
GI50 for single agent treatments are plotted on a semi-logarithmic scale in which x-axis
(log10 scale) indicates drug concentrations and y-axis represents % effect on cell viability
as measured by 48-hour MTT assays. Data were analyzed by non-linear regression
analysis to generate sigmoidal dose response curves. Data points represent mean values
from three independent experiments ± SD. A: The effects of single treatment by LDN193189 on the percent of viable LP T65(Nf1-/-) cells, GI50: 0.1 ± 0.4 and HP T65(Nf1-/-)
cells, GI50 2.1 ± 0.1. B: The effects of single treatment by AZD6244 on the percent of
viable LP T65(Nf1-/-), GI50: 3.5 ± 0.2, and HP T65(Nf1-/-) cells, GI50: 9.1 ± 0.4, as measured
by 48 hour MTT assay. C and D: Standard isobologram analyses of the interactions
between LDN-193189 and AZD6244 on cell viability. All drug combinations exhibit a
synergistic effect in both low and high passage cells with increased synergy reported in
the LP T265(Nf1-/-) cells. Each axis represents the indicated concentrations of that drug.
Data points represent the average value from three independent experiments ± SD.
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CI values
MPNST cell lines
Combination
Drug
Treatments

STS26TV (Nf1+/-)

STS26TNf1 KD

LP

HP

LP

HP

ST88-14

ST88-14

T265

T265

-/-

-/-

-/-

(Nf1 )

(Nf1 )

(Nf1 )

(Nf1-/-)

LDN-193189
+0.1µM AZD

0.73

0.65

0.58

0.85

0.62

0.99

LDN-193189
+0.3µM AZD

0.64

0.61

0.39

0.86

0.48

0.99

LDN-193189
+1.0µM AZD

0.55

0.74

0.32

0.91

0.37

0.71

LDN-193189
+3.0µM AZD

0.68

0.67

0.92

0.84

0.78

0.65

Table 2: CI values for combination treatment of MPNST cells. CalcuSyn software
was used to calculate the combination index (CI), according to the median-effect method
of Chou-Talay. CI values less than 1, 1, and greater than 1, represent synergism,
additivity, and antagonism, respectively. The combinatorial treatment has a synergistic
effect on cell viability in the STS26T-V(Nf1+/-) and STS26T-Nf1 KD cell lines. HP ST8814(Nf1-/-), and HP T265(Nf1-/-) trend towards additivity at lower concentrations of
AZD6244, however, increasing the dose of AZD6244 increases synergy in these cell
lines. Both LP ST88-14(Nf1-/-) and T265(Nf1-/-) cells exhibit a strong synergistic
interaction at lower doses of AZD6244 combined with LDN-193189. The CI values shown
are averages of CI values of three independent experiments per cell line and treatment
conditions.
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3.3.4

The effects of combinatorial targeting of BMP2 and MEK1/2 signaling

pathways on cellular migration and invasion in MPNSTs µM
Metastases of MPNSTs occurs in about 39% of patients (Panigrahi et al. 2013)
with the most frequent metastatic sites being lungs, lymph nodes, and liver (Wong et al.
1998). As expression of Bmp2 positively correlates with malignancy in neurofibromas
(Miller et al. 2009), increased expression of BMP2 in MPNSTs may promote metastatic
characteristics such as cell migration and invasion. To investigate the effects of BMP2
on migration and invasion of MPNST cell lines upon treatment with LDN-193189 and/or
selumetinib, we employed an in vitro wound healing assay and a basement membrane
invasion assay.
To determine the nature of the therapeutic interaction of LDN-193189 and
selumetinib on migration and invasion of MPNST cells, Bliss Independence (BI) model
was used. BI model assumes different, independent, mutually nonexclusive sites of
action for the candidate agents (Geary 2013; Foucquier & Guedj 2015), which is the case
in this study.

Based on the western blot analyses [Figs. 3.1(C), 3.2(C)], the

concentrations used in the migration and invasion assays for LDN-193189 (0.01 µM, 0.1
µM) do not affect phosphorylation of ERK1/2, and treatment with 0.03 µM and 0.3 µM
selumetinib has no effect on the phosphorylation of SMAD1/5/8 in the MPNST cell lines.
3.3.4.1 Combinatorial treatment with LDN-193189 and selumetinib does not affect
cellular migration as compared to single treatment with LDN-193189 in MPNST cells
For the wound healing assay, cell lines were treated with two concentrations of
LDN-193189 (0.01 and 0.1 µM) and selumetinib (0.03 and 0.3 µM), which result in
biochemical inhibition of their respective targets as per the length of the wound healing
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assay. It is important to note that cell viability and growth, as tested by the MTT assay,
is unaffected by the concentration of the drugs used for the migration and invasion studies
[see results section 3.3.3]. For the wound healing assay, cells were plated in 24-well
plates on either side of the wound area made by inserts. After 24 hours of plating, the
inserts were removed, and cells were washed and treated with the indicated
concentration of the drugs. As the vehicle control treated cells were unable to close the
gap of the wound area within 24 hours of treatment, the wound healing assay was
extended to 48 hours with a daily dose of the indicated drugs. Fluorescent images were
captured prior to the drug treatments (pre-treatment), 24 hours, and 48 hours posttreatment and quantified by the wound healing module of the Image Pro software.
Representative images of the analysis with wound areas highlighted in blue are shown
for one of the treatment conditions for each cell line. The boundaries of the wound field
created by the cells are based on the selected thresholds for each image and background
fluorescence intensity is subtracted per image. Cell migration to the wound field at 24 h
and 48 h time intervals is normalized to the area of the wound in pre-treatment conditions.
Treatment with 0.01 µM and 0.1 µM LDN-193189 effectively reduces the cell
migration field of LP ST88-14(Nf1-/-) and LP T265(Nf1-/-) cells [Figs. 3.7, 3.8]. Selumetinib
(0.03 µM) has no effect on migration in any of the tested cell lines as compared to the
control.

However, increasing the dose of selumetinib to 0.3 µM inhibits migration

significantly in both the low passage cell lines. Even though the combination treatment
in the low passage cells reduces migration, this effect is insignificant as compared to
single treatment with LDN-193189. Based on the BI calculations, the combinatorial
effects of these drugs trend from additivity to antagonism, with the exception of LP ST88-
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14 which shows a weak synergistic interaction of the drug combination when treated with
0.01 µM LDN-193189 and 0.03 µM selumetinib. Similarly, the migratory ability of both
HP ST88-14(Nf1-/-) and HP T265(Nf1-/-) cells is greatly reduced by LDN-193189.
However, addition of selumetinib lowers the inhibitory effect on migration by single
treatment with LDN-193189, resulting in a strong antagonistic effect [Figs. 3.9, 3.10].
Results from the wound healing assays suggest that the addition of selumetinib to
LDN-193189 does not significantly affect cellular migration as compared to single
treatment with LDN-193189, which has a strong effect on cellular migration by itself in
MPNST cells. Interestingly, low passage Nf1(-/-) MPNST cells are more sensitive to
selumetinib in regards to their migratory potential as compared to the high passage Nf1(/-)

MPNST cells. We had also found the low passage Nf1(-/-) MPNST cells to be more

sensitive to selumetinib in cell viability assays [see results section 3.3.3].
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Figure 3.7: The combinatorial treatment with LDN-193189 and selumetinib (AZD6244)
does not affect cellular motility in LP ST88-14(Nf1-/-) cells. A: Representative images of
the analyzed cellular wound area of LP ST88-14(Nf1-/-) cells taken at different time points during
the course of the migration assay. The highlighted blue lines represent the analyzed wound area.
B: The percent quantification of the wound area was normalized to the pre-treatment wound area
for each condition. LDN-193189 (0.01 µM, 0.1 µM) reduces the motility of LP ST88-14 cells
(P<0.001). AZD6244 affects motility only at a higher concentration of 0.3 µM (P<0.001). The
combination of both the drugs results in an insignificant decrease in motility, as compared to single
treatment with LDN-193189. BI values represent a low synergistic to additive effects of the drug
combinations. Data presented are the mean average of quantification of the wound areas of at
least three independent experiments ± S.D (n=3, One-way ANOVA for single treatments as
compared to control, Two-way ANOVA for combination treatments compared to LDN-193189
followed by Tukey’s test for multiple comparisons).
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Figure 3.8: The combinatorial treatment with LDN-193189 and selumetinib (AZD6244)
does not affect cellular motility in LP-T265 (Nf1-/-) cells. A: Representative images of the
analyzed cellular wound area of LP T265(Nf1-/-) cells taken at different time points during the
course of the migration assay. The highlighted blue lines represent the analyzed wound area.
B: The percent quantification of the wound area was normalized to the pre-treatment wound
area for each condition. LDN-193189 (0.01 µM, 0.1 µM) reduces the motility of LP T265 cells
as compared to the control (P<0.0001). AZD6244 affects motility only at a higher
concentration of 0.3 µM (P<0.001). The addition of AZD6244 to LDN-193189 does not
significantly affect motility as compared to single treatment with LDN-193189. BI values
represent an antagonistic effect of drug combinations on motility. Data presented are the
average of quantification of the wound areas of at least three independent experiments ± S.D
(n=3, One-way ANOVA for single agent treatments as compared to control, Two-way ANOVA
for combination treatments compared to single treatment with LDN-193189 followed by
Tukey’s test for multiple comparisons).
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Figure 3.9: The combinatorial treatment with LDN-193189 and selumetinib (AZD6244) does
not affect cellular motility in HP ST88-14(Nf1-/-) cells. A: Representative analyzed images of
the cellular wound area of HP ST88-14(Nf1-/-) cells taken at different time points during the course
of the migration assay. The highlighted blue lines represent the analyzed wound area. B: The
percent quantification of the wound area was normalized to the pre-treatment wound area for
each condition. LDN-193189 (0.01 µM, 0.1 µM) reduces the motility of HP ST88-14 cells in a
concentration dependent manner respectively (P<0.01, P<0.001). 0.03 µM AZD6244 does not
affect motility, however 0.3 µM inhibits motility (P<0.05). The combination treatment does not
affect migration in HP ST88-14 as compared to single treatment with LDN-193189. BI values
represent an antagonistic effect of drug combinations on motility. Data presented are the average
of quantification of the wound areas of at least three independent experiments ± S.D (n=3, Oneway ANOVA for single agent treatments as compared to control, Two-way ANOVA for
combination treatments compared to single treatment with LDN-193189 followed by Tukey’s test
for multiple comparisons).
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Figure 3.10: The combinatorial treatment with LDN-193189 and selumetinib (AZD6244)
does not affect cellular motility in HP T265(Nf1-/-) cells. A: Representative of the analyzed
cellular wound area of HP T265(Nf1-/-) cells taken at different time points during the course of the
migration assay. The highlighted blue lines represent the analyzed wound area. Wound healing
assay for HP T265 cells was terminated at 24 hours post-treatment because the wound area of
the vehicle treatment condition had almost closed. B: The percent quantification of the wound
area was normalized to the pre-treatment wound area for each condition. LDN-193189 (0.01 µM,
0.1 µM) reduces the motility of HP T265 cells (P<0.0001). Only the high concentration of
AZD6244 at 0.3 µM affects motility in the HP T265 cells (P<0.05). The addition of AZD6244 to
LDN-193189 in combination treatment does not affect the migratory potential of HP T265 cells as
shown by insignificant differences in percent wound closure. BI values represent an antagonistic
effect of drug combinations on motility. Data presented are the average of quantification of the
wound areas of at least three independent experiments ± S.D (n=3, One-way ANOVA for single
agent treatments as compared to control, Two-way ANOVA for combination treatments compared
to single treatment with LDN-193189 followed by Tukey’s test for multiple comparisons).
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3.3.4.2 Combinatorial treatment with LDN-193189 and selumetinib does not affect
cellular invasion as compared to single treatment with LDN-193189
The effect of BMP2 and MEK1/2 signaling pathways on the invasive properties of
MPNST cells was measured by a basement membrane invasion assay. The invasion
assay was performed in 96-well plates, the upper chamber of which was coated with
extracellular matrix (ECM) gel and the cells that digested and invaded through the ECM
were quantified by a fluorescence plate reader. FBS was used at 10% in media as the
chemoattractant in the bottom chamber. Fluorescence readings of duplicate wells without
any chemoattractant per cell line were subtracted from all experimental conditions. Next,
wells with variable treatments were normalized to vehicle-controls of the respective
treatment. To certify that the effects on invasion by LDN-193189 are specific to BMP2,
recombinant BMP2 protein with or without LDN-193189 was added to the serum free
media of the suspended cells. The effects of LDN-193189 and selumetinib on cell
invasion of MPNST cells were assessed by single doses and combination doses of these
agents.
The invasive capability of the tested MPNST cell lines is significantly increased by
200 ng/ml BMP2 stimulation, and the addition of LDN-193189 completely blocks the
effects induced by BMP2 on MPNST cell invasion [Fig. 3.11]. Both LP and HP Nf1(-/-)
cells responded to LDN-193189 treatment with a significant decrease in invasion [Fig
3.12(A) and (B)]. As seen in the migration analyses, single treatment with 0.3 µM
selumetinib significantly affects invasion of the LP MPNST cells, however this effect is not
as pronounced as that of LDN-193189. Upon combination treatment with LDN-193189
and selumetinib, the invasive capability of both LP ST88-14(Nf1-/-) and LP T265(Nf1-/-)
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cell lines is reduced, however the effect is statistically insignificant [Fig. 3.12(A), Fig.
3.12(B)]. The combinatorial effect on invasion of both the drugs in the LP MPNST cells
trends from a weak synergistic effect to an additive effect. In the HP ST88-14(Nf1-/-) and
HP T265(Nf1-/-), LDN-193189 significantly inhibits invasion, whereas addition of
selumetinib has no effect on the invasive capability as compared to treatment with LDN193189 alone [Fig. 3.12(C), 3.12(D)].
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Figure 3.11: LDN-193189 rescues the effects of BMP2 on cellular invasion in
MPNST cell lines. Graphical representations of the quantified fluorescence of the cells
that invaded through the ECM, normalized to invasive activity without any
chemoattractant and the vehicle control. LDN-193189 inhibits cellular invasion as
compared to the vehicle treated control in LP and HP Nf1(-/-) MPNST cells. Addition of
200ng/mL BMP2 promoted invasion in these cells (P<0.01), which is blocked by the
addition of LDN-193189 in all the tested MPNST cells. Cells were stained with
CyQuant/GR dye and the number of invaded cells was quantified by a fluorescence plate
reader. Data presented are mean average of three independent experiments ± S.D with
the corresponding P-values (n=3, One-way ANOVA followed by Tukey’s test for multiple
comparisons).
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Figure 3.12:
The effects of combination treatment with LDN-193189 and
selumetinib (AZD6244) on the invasion of Nf1(-/-) MPNST cells.
Graphical
representations of the quantified fluorescence of the cells that invaded through the ECM,
normalized to invasive activity without any chemoattractant and the vehicle control. A
and B: The percentage of low passage cells invading through the ECM using LDN193189 and selumetinib. The invasive ability of LP cells is greatly reduced by LDN193189 (0.01 µM, 0.1 µM), whereas selumetinib only affects cellular invasion at 0.3 µM.
The combinatorial treatment does not result in an enhancement of the inhibitory effect of
LDN-193189 on invasion. Based on the BI model, the therapeutic interaction of the
combination treatment on invasion is weakly synergistic. C and D: The percentage of
high passage cells invading through the ECM using LDN-193189 and selumetinib. The
invasive ability of HP cells is greatly reduced by LDN-193189 (0.01 µM, 0.1 µM), whereas
selumetinib only affects cellular invasion at 0.3 µM. BI values indicate a weakly
synergistic to an additive interaction of the combination treatment on invasion. Data
presented are the mean average of three independent experiments ± S.D. with
appropriate P-values shown on the graph, (n=3, One-way ANOVA for single agent
treatments as compared to the controls followed by Tukey’s test for multiple comparisons,
Two-way ANOVA for combination treatments as compared to single agent treatments
with LDN-193189, followed by Tukey’s test for multiple comparisons).
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3.4 Conclusions
The data presented in this chapter have established the functional significance of
targeting BMP2 in MPNST cells. Inhibition of BMP2 by LDN-193189, not only decreases
cell migration and invasion but also cell viability in MPNST cell lines. Inhibition of cell
viability by LDN-193189 is an off-target effect in the MPNST cells, given that the cell
viability GI50s are at least 10-fold higher than the biochemically effective dose required to
inhibit SMAD1/5/8 signaling. Interestingly, an independent study of the effects of LDN193189 on viability of three pancreatic cancer cell lines corroborates our results as LDN193189 decreases viability of pancreatic cancer cell lines within the concentration ranges
used in our MTT experiments (Voorneveld et al. 2013). These off-target effects of LDN193189 may be modulated by targeting of receptors or kinases other than BMP Type I
receptors. In fact, a study of kinase specificity of LDN-193189 determined that at 1.0 µM
concentration (within cell viability GI50 range in MPNST cells), LDN-193189 affects 24
kinases notably RIPK2, GCK, FGF-R1, etc, independent of its effects on the
phosphorylation of SMAD1/5/8 complex (Vogt et al. 2011). Kinases involved in the MAPK
pathway were unaffected by 1.0 µM LDN-193189 in the same study, and results from our
western blots conclude that treatment with up to 1.0 µM LDN-193189 does not affect
MEK1/2 in MPNST cell lines. Conclusively, LDN-193189 and selumetinib via off-target
effects, synergize to decrease cellular viability in various MPNST cell lines. We cannot
speculate on the mode of decrease in cellular viability at this time as inhibition of viability
by apoptosis, necrosis, or cytostatic effects cannot be distinguished by the MTT assay
employed in this study.
Given that BMP2-SMAD1/5/8 pathway is involved in cellular migration and
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invasion, inhibition of these malignant characteristics by LDN-193189 in MPNST cells
was expected. Results presented in this chapter corroborate the decrease in motility and
invasiveness by LDN-193189 in MPNST cells previously tested in the HP Nf1(-/-) MPNST
cells by our lab (Sun et al. 2013). However, we did not expect changes in the migratory
and invasive potential of the tested cell lines upon treatment with selumetinib.
Selumetinib is a specific inhibitor of MEK1/2 signaling that is primarily involved in the
regulation of cell viability, growth and proliferation. Results from the in vitro migration and
invasion studies indicate that selumetinib, in addition to suppressing the growth of
MPNSTs, may also provide a significant benefit by inhibiting the invasiveness of such
tumors. However, the combination treatment with both the candidate agents does not
result in a significant change in the motility and invasiveness of MPNST cell lines as
compared to single treatment with LDN-193189. In fact, the combinatorial effect on
migration is antagonistic in nature. Interestingly, even though the combination treatment
does not significantly affect invasion of MPNST cells as compared to treatment with LDN193189 alone, the nature of the combinatorial interaction is weakly synergistic and
additive. This is because the BI model takes into account the effects of single treatment
with both the candidate agents, whereas for statistical analyses combinatorial treatment
was only compared to single treatment with LDN-193189. Accordingly, in comparing the
effects of combination treatment versus selumetinib alone, the combination significantly
decreases invasion (P<0.01) in all the tested MPNST cells. However, the purpose of
these experiments was to assess the feasibility of combination treatment versus single
treatment with LDN-193189.

Therefore, due to insignificant differences between

combination treatments and single treatment with LDN-193189, the addition of

93

selumetinib to LDN-193189 does not affect cellular migration and invasion of MPNST
cells.
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CHAPTER IV: Mechanistic studies of BMP2 regulation by NF1 in MPNSTs
4.1 Summary
The importance of targeting the BMP2-SMAD1/5/8 signaling pathway in MPNSTs
is highlighted by the reversal of invasiveness and migration of MPNST cells as presented
in Chapter III. Even though small molecule inhibitors such as LDN-193189 are effective
at inhibiting BMP2-SMAD1/5/8 signaling, the potential off-target effects of protein
targeting molecules limit the efficacy of pharmacological inhibition.

The unintended

inhibition of receptors/kinases other than the targeted protein may be harmless or toxic
depending on the affected cells and the signaling pathways involved. Gene therapy
provides us with an alternative methodology to pharmacological inhibition, in which the
specificity of targeting the gene of interest minimizes off-target effects. Our goal in this
chapter is to identify a genetic target of increased Bmp2 expression by Nf1 deficiency in
MPNSTs; for which, an understanding of the regulatory mechanisms by which NF1
deficiency results in activation of BMP2-SMAD1/5/8 pathway, is warranted.
To understand the molecular mechanisms underlying Bmp2 expression patterns
in MPNSTs, it is important to identify the transcriptional regulatory elements associated
with Bmp2 upon down-regulation of Nf1.

Data presented in this chapter identified

regulatory elements that control Bmp2 expression in MPNSTs, by transcriptional and
post-transcriptional analyses of Bmp2 in Nf1(+/-) and Nf1 knockdown conditions. Multiple
levels of genetic regulation of Bmp2 by Nf1 were explored via Bmp2 promoter analysis,
determination of mRNA half-life, and studies of the Bmp2 3’UTR. These mechanismbased studies enabled the identification of genetic targets of Bmp2 up-regulation that can
be targeted to reduce the migration and invasion of MPNSTs.
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4.2 Materials and Methods
4.2.1 Construction of plasmids
For the Bmp2 promoter assay, eight fragments of the human Bmp2 promoter
including the distal and proximal TSSs spanning 1786 nucleotides were cloned into the
SacI and XhoI restriction sites of the pGL3 luciferase promoter vector (Promega,
Madison, WI, USA).

Cloning was performed using the InFusion® HD cloning kit

(Clontech, Mountainview, CA, USA). To investigate the human Bmp2 3’UTR, full length
human Bmp2 3’UTR was isolated using standard PCR from CRL-2522 cells. The isolated
3’UTR fragments were cloned into the DraI and XbaI restriction sites of the pmiRGLO
luciferase reporter expression constructs (Promega, Madison, WI, USA). InFusion® HD
cloning system was used for cloning the 3’UTR fragment placed between the luciferase
gene and the polyadenylation site of the pmiRglo vector. All constructs were analyzed by
restriction mapping and DNA sequencing.
4.2.2 Promoter assays and transient transfections
Promoter reporter experiments were performed in STS26T-V(Nf1+/-), and STS26TNf1 KD. Cells were seeded on 96-well plates, and were transiently transfected with the
prepared luciferase vectors and the control pGL3 promoter vector (Promega, Madison,
WI, USA). DNA transfection was carried out using Xtremegene 9 (Roche life sciences,
Indianapolis, IN, USA). For each well, 0.05 µg of the luciferase vector was mixed with
0.02ng of pRL–SV40 renilla luciferase control expression vector (Promega, Madison, WI,
USA). The DNA concentration for transfection was optimized by titration prior to the
actual experiments. The mixture was then added to 0.15 µl of the transfection reagent,
in 5 µl of OptiMem reduced serum media (Life Technologies, Grand Island, NY, USA).
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The mixture was incubated for 30 min at room temperature. The reagent mixture was
combined with 100 µl of the complete culture medium, and subsequently added to the
washed cell monolayer in each well. The transfected cells were cultured for 36-48 hours
and then lysed in 25 µl of the reporter lysis buffer per well (Promega, Madison, WI, USA).
Twenty microliters of lysate was transferred to opaque white polystyrene 96-well plates
(Sigma-Aldrich, St. Louis, MO, USA). Luciferase activity was assayed on GloMax® 96
Microplate Luminometer using a Dual-Glo luciferase assay system (Promega, Madison,
WI, USA).

Each condition had 8 replicates and all transfection experiments were

repeated a minimum of 3 times.
4.2.3 Bmp2 3’UTR analysis and transient transfections
Analysis of the human Bmp2 3’UTR was performed on the STS26T-V(Nf1+/-),
STS26T-Nf1 KD, Cond KD#1 (+/- dox), Cond KD#2 (+/- dox), and Cond KD#3 (+/doxycycline) cells. For a detailed explanation of the conditional KD cell lines, refer to
Chapter II. Cells were plated on 96-well plates, and were transiently transfected with the
prepared luciferase vectors and the control pmirGLO vector (Promega, Madison, WI,
USA). DNA transfection was carried out using Xtremegene 9 (Roche life sciences,
Indianapolis, IN, USA). For each well, 0.05 µg of the luciferase vector was mixed with
0.15µl of the transfection reagent, in 5 µl of OptiMem reduced serum media (Life
Technologies, Grand Island, NY, USA). The mixture was incubated for 30 min at room
temperature. The reagent mixture was combined with 100 µl of the complete culture
medium, and subsequently added to the washed cell monolayer in each well. Renilla
luciferase vector was not added in these experiments as the pmirGLO vector contains an
internal renilla (hRluc-neo fusion) expression construct.

The transfected cells were
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cultured for 24-36 hours and then lysed in 25 µl of the reporter lysis buffer per well
(Promega, Madison, WI, USA). Twenty microliters of each lysate was transferred to
opaque white polystyrene 96-well plates (Sigma-Aldrich, St. Louis, MO, USA). Luciferase
activity was assayed on GloMax® 96 Microplate Luminometer using a Dual-Glo luciferase
assay system (Promega, Madison, WI. USA). Each condition had 8 replicates and all
transfection experiments were repeated a minimum of 3 times.
4.2.4 RNA extraction and quantitative real time PCR
RNA was extracted from 10 mm plates of 70-85% confluent cells using the RNeasy
Mini Kit (#74106, Qiagen, Valencia, CA, USA). Three batches of total RNA (2.0 µg) for
each cell line were reverse transcribed by SuperScript® II First-Strand Synthesis System
(Invitrogen, Waltham, MA, USA). Q-RT-PCR was performed using Power SYBR Green
MasterMix (Applied Biosystems, Carlsbad, CA, USA) and analyzed on the ABI 5700
Sequence Detection System (Applied Biosystems, Carlsbad, CA, USA). Primers for each
gene analyzed are listed in Table 4.1. For mRNA half-life experiments, 18S was used as
the reference gene due to its prolonged half-life and stability. The relative fold change
was calculated using the CT method as follows: 2-ΔΔCT, where, ΔΔCT = (CT Bmp2 - CT18S)
experimental time - (CT Bmp2 - CT18S) 0 time point. Statistical significance was determined
through student’s t-test and a p-value of less than 0.05 was considered significant.
Table 3: Primer sequences used to determine Bmp2 half-life by qRT-PCR
Gene

Forward

Reverse

Bmp2

GACACTGAGACGCTGTTCC

CCATGGTCGACCTTTAGG

18S

GTAACCCGTTGAACCCCATT

CCATCCAATCGGTAGTAGCG
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4.3 Results
Transcriptional regulation is a dynamic web of tightly controlled processes, which
spatially and temporally dictate gene expression. Most notably, the expression of a given
gene is regulated by initiation of transcription via gene-specific promoters, pre-mRNA
processing, and mRNA stability. To identify the mechanism of increased Bmp2 transcript
levels by down-regulation of NF1, we investigated the transcriptional regulation of Bmp2
by the initiation of transcription through Bmp2 promoter analysis, and post-transcriptional
regulation by Bmp2 mRNA stability and 3’UTR activity upon knockdown of Nf1 in
MPNSTs. The experiments presented in this chapter were performed in two independent
Nf1 knockdown cell models detailed in Chapter II. Comparison of the mechanistic data
between the stable knockdown of Nf1 and the inducible Nf1 knockdown system serves to
minimize cell line or knockdown vector-specific variations.
4.3.1 NF1 does not regulate Bmp2 promoter activity in MPNST cells
The promoter region of a gene is located in the distal 5’ end of a given gene, which
is composed of specific sequences of regulatory elements that control the initiation of
transcription of that gene.

The combinatorial input of various elements within the

promoter region such as TSSs, TF-binding sites, and interaction of cis- and transregulatory elements i.e. enhancers or repressors, determine the steady-state levels of
transcription of a given gene (Maston et al. 2006).

Bmp2 is regulated by highly

guanine/cytosine (GC)-rich distal and proximal promoter regions (Jiang et al. 2010), with
greater activity reported in the proximal promoter TSS (Helvering et al. 2000; GhoshChoudhury et al. 2001). The GC-rich promoter regions of Bmp2 are characteristic of
transcriptionally repressed genes. Thereby, Bmp2 transcription requires a balancing of
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activating factors with the repressive factors to initiate Bmp2 transcription (Jiang et al.
2010). To understand the regulatory elements governing the activation of Bmp2 by Nf1,
we conducted an analysis of the promoter activity of Bmp2 upon Nf1 knockdown.
Based on published human Bmp2 promoter sequences (Helvering et al. 2000;
Jiang et al. 2010), eight promoter constructs spanning ~1.8 kb of the Bmp2 gene
containing the distal and proximal promoter TSSs were cloned into a pGL3 promoter
luciferase reporter vector [Fig. 4.1(A) and 4.1(B)].

These vectors were transiently

transfected into the STS26T-V(Nf1+/-) and STS26T-Nf1 KD cells in which the intensity of
the luciferase signal is proportional to the activity of the Bmp2 promoter regions. Analysis
of the luciferase activity comparing the Bmp2 promoter activity in the STS26T-V(Nf1+/-)
and STS26T-Nf1 KD cells did not show any significant changes in the vector control and
Nf1 KD cells [Fig. 4.1(C)]. The full-length promoter construct (-1000 to +786 nt) shows
the least luciferase activity, whereas the region spanning (+494 to +675 nt) has the
highest luciferase activity. Therefore, 181 nucleotides of the promoter region between
+494 and +675 consist of activating Bmp2 elements in the sporadic MPNST cell line. Due
to the inability to find any difference in Bmp2 promoter activity upon Nf1 knockdown
between the STS26T-V(Nf1+/-), STS26T-Nf1 KD, I concluded that the Bmp2 promoter was
not the region of the genome regulating Nf1 regulation of BMP2 expression in MPNSTs.
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Figure 4.1: NF1 does not regulate activity of the Bmp2 promoter in MPNSTs. A:
The pGL3-promoter luciferase reporter vector construct used for cloning fragments of the
Bmp2 promoter. B: Schematic of the Bmp2 promoter fragments cloned upstream of the
luciferase gene in the promoter vector. C: Representative analysis of the luciferase
activity, normalized to renilla in the STS26T-V(Nf1+/-) and STS26T-Nf1 KD cells shows no
significant change in activity of the Bmp2 promoter upon Nf1 knockdown conditions.
Paired t-test, n=8, ns. Data presented are mean of three independent experiments with
average of eight replicates per condition ± S.D.
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4.3.2 The post-transcriptional regulation of Bmp2 by NF1
Because I did not find any changes in the activity of Bmp2 promoter based on NF1
status, I investigated the post-transcriptional regulation of Bmp2 upon knockdown of Nf1.
There are multiple levels of post transcriptional regulatory mechanisms such as mRNA
processing, splicing, polyadenylation, editing, transport, and stability (Day & Tuite 1998).
Among which, the expression of 5-10% of human genes is controlled by mRNA stability
(Bolognani & Perrone-Bizzozero 2008). Analysis of the post-transcriptional regulation of
Bmp2 was conducted by determining the differences in the rate of Bmp2 mRNA turnover,
followed by analysis of the Bmp2 3’UTR between Nf1(+/-) and Nf1 knockdown conditions.
4.3.2.1 NF1 regulates Bmp2 mRNA stability
Stability of a given mRNA is a major determinant of its expression. Regulation of
mRNA turnover controls the abundance of cellular transcripts, hence the levels of protein
expression (Wilusz et al. 2001).

Each mRNA has an intrinsic half-life, however

intracellular and extracellular stimuli can modulate the half-life of a given mRNA (Chen et
al. 2008). In vitro analyses of Bmp2 mRNA decay rates has shown that half-life of Bmp2
mRNA correlate with the endogenous mRNA levels of Bmp2 in human, mouse, and
zebrafish cells (Fritz et al. 2004).
To investigate the changes in the rate of Bmp2 mRNA turnover between Nf1(+/-)
and Nf1 knockdown conditions, I determined the half-life of Bmp2 mRNA under both
conditions.

Determination of the Bmp2 mRNA half-life was performed by using

actinomycin D to inhibit global transcription within the cells, followed by quantification of
the Bmp2 mRNA levels by qRT-PCR at various time points under the Nf1(+/-) and Nf1
knockdown conditions.

Actinomycin D is a widely used transcriptional inhibitor that
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inhibits DNA-dependent RNA synthesis. Actinomycin D intercalates into single stranded
DNA (ssDNA) and prevents the annealing of the newly synthesized (-) ssDNA to the
acceptor RNA, specifically RNA polymerase I (Jeeninga et al. 1998; Sobell 1985), which
leads to inhibition of transcription. Cells were treated with actinomycin D (5 µM), after
which RNA was extracted at intervals of 0, 1, 3, 6, 9, 12 and 24 hours. qRT-PCR was
used to determine the expression of Bmp2 at these intervals to determine the mRNA halflife of Bmp2 over the course of 24 hours. The 18S ribosomal RNA gene was used as the
reference gene due to its increased stability and prolonged half-life. The fold changes in
Bmp2 transcript levels were normalized to Bmp2 levels at the 0 time point per cell line.
RNA extracted at the 24 hour time point for each cell line was excluded from data
analyses due to high Ct values that may skew the final determination of half-lives. The
half-lives of the Bmp2 transcripts were calculated by determination of the decay rate
constant (kdecay) per experiment, which is proportional to the rate of disappearance of the
mRNA concentration at a given time point. Fold changes were plotted on a semilogarithmic scale, and non-linear regression analysis was used to determine the slope of
the best-fit line, which represents kdecay. mRNA half-life (t1/2 ) is then calculated by the
following equation: t1/2 = ln 2/kdecay (Chen et al. 2008).
As shown in Figure 4.2(A) and Table 4, mRNA half-life in the STS26T-Nf1 KD cells
is almost double, 4.4 hours, as compared to the half-life of STS26T-V(Nf1+/-) cells at 2.3
hours. This doubling of Bmp2 mRNA half-life correlates with the steady state Bmp2
mRNA levels upon Nf1 KD as measured in Fig 2.4, where Bmp2 mRNA levels increase
almost two-fold in the STS26T-Nf1 KD cells as compared to the STS26T-V(Nf1+/-) cells.
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To validate the changes in Bmp2 mRNA half-life depending on the status of Nf1,
three inducible Nf1 knockdown cell lines were used. This approach provides a tight and
rapid genetic switch to control levels of NF1 within cells, therefore any resulting changes
in Bmp2 transcription can be ascertained to changes in the NF1 status within the same
cell population. The inducible Nf1 KD clones were treated with doxycycline (2 µg/ml) to
induce the Nf1 shRNA 18 hours prior to treatment with actinomycin D. All of the inducible
Nf1 KD cell lines show a decrease in the degradation of Bmp2 transcript upon treatment
with actinomycin D [Fig 4.2 (B), (C), and (D)], and a 1.5-2.0 fold increase in Bmp2 mRNA
half-life upon down-regulation of Nf1. These increases in Bmp2 half-life upon knockdown
of Nf1 are comparatively similar to the increases in steady state Bmp2 transcript levels
under the same conditions, as shown in Fig. 2.8. For example, the steady state Bmp2
mRNA levels in the Cond KD#3 increase ~1.8 fold upon induction of the Nf1 shRNA [Fig.
2.8] and the Bmp2 mRNA half increases by 1.9 fold [Table 4].
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Figure 4.2: The rate of Bmp2 mRNA decay decreases upon NF1 downregulation in
MPNST cells. Changes in Bmp2 mRNA levels are plotted on a semi-logarithmic scale
and non-linear regression analysis is used to draw a straight line through the data points.
A: Bmp2 transcripts in the STS26-T Nf1 KD cells degrade slower than those in the
STS26T-V(Nf1+/-) cells upon treatment with actinomycin D. Paired t-test, n=3, P<.05. Data
presented are mean of three independent experiments ± S.D. B, C, and D: Induction of
the Nf1 shRNA by treatment with doxycycline induces an increase in Bmp2 transcripts
over the course of 12 hours in three independent conditional Nf1 knockdown cells. Data
presented are mean of at least three independent experiments ± S.D.
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t1/2 (hours)
Cell lines

Vector Ctrl
(Nf1+/-)

Nf1 KD

P-value

STS26T (Nf1+/-)

2.3 ± 0.2

4.4 ± 0.5

0.02

Cond KD #1

1.8 ± 0.2

2.9 ± 0.8

0.07

Cond KD #2

2.4 ± 0.1

4.3 ± 0.4

0.01

Cond KD #3

2.1 ± 0.3

4.0 ± 0.6

0.03

Table 4: Comparison of Bmp2 mRNA half-lives between Nf1(+/-) and Nf1 KD cells.
Mean Bmp2 mRNA half-life in MPNST cells as calculated by the method described in the
results section (t1/2 = ln2/kdecay). Upon down-regulation of Nf1 Bmp2 mRNA half-life
almost doubles in all of the tested cell lines. The doubling of half-life correlates with
steady state Bmp2 expression levels per cell line. t1/2 shown is the average of half-life
calculations from three independent experiments.
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4.3.2.2 NF1 regulates Bmp2 3’UTR
The stability of mRNA is controlled by its 3’-untranslated region (3'-UTR), which
consists of regulatory sequences that post-transcriptionally influence gene expression.
Remarkably, regulatory elements within the Bmp2 3’UTR are well-conserved across
species (Fritz et al. 2004) and more conserved than its coding region (Abrams et al. 2004),
which is indicative of its important role in the regulation of Bmp2 expression. The 3’UTRs
of the human and mouse Bmp2 transcripts are 83% identical over 1,088 nucleotides, and
high degree of conservation of Bmp2 3’UTR is reported between several mammalian
orders (Fritz et al. 2004).
To further explore the regulation of Bmp2 stability upon knockdown of Nf1, I
assessed the activity of Bmp2 3’UTR under Nf1(+/-) and Nf1 knockdown conditions. Fulllength human Bmp2 3’UTR (3530 nucleotides) was isolated from normal human
fibroblasts and cloned into a pmirGLO luciferase reporter vector [Fig. 4.3(A)] between the
luciferase gene and the polyadenylation site of the vector. All cell lines were transfected
with the control vector and the vector containing the Bmp2 3’UTR sequence. The intensity
of the luciferase signal is proportional to the activity or stability induced by the Bmp2
3’UTR. Luciferase activity for each Nf1-KD cell line is normalized to its control (Nf1+/-).
Figure 4.3(B) shows that Bmp2 3’UTR activity in the STS26T-Nf1 KD cells is
approximately 4.5 fold higher in the STS26T-Nf1 KD cells as compared to the vector
control. For the inducible Nf1 knockdown cell models, Nf1 shRNA was induced by
doxycycline (2 µg/ml) 10 hours post-transfection to limit any effects of doxycycline on
transfection conditions. All three inducible Nf1 KD cells exhibit increased Bmp2 3’UTR
activity [Fig. 4.3(C)], with highest relative activity reported in the Cond KD#3 which also
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has the highest fold change in steady-state expression levels and mRNA half-life. The
increase in Bmp2 3’UTR activity in the inducible Nf1 knockdown cells is not as
pronounced as that of the STS26T-Nf1 KD cells. The average 1.8-2.4 fold increase in
Bmp2 3’UTR activity in dox-treated cells, after subtraction of the luciferase signal from
untreated cells is similar to the steady state Bmp2 mRNA levels and its half-life upon
knockdown of Nf1. The increased activity (~4.5 fold) of the Bmp2 3’UTR in the STS26TNf1 KD compared to the STS26T-V(Nf1+/-) cells can be attributed to analysis of the 3’UTR
activity in two different cell populations. The inducible knockdown system represents a
better, more specific model to study the direct effects of NF1 on the Bmp2 3’UTR as
analysis is conducted within the same cell population.
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Figure 4.3: Activity of the Bmp2 3’UTR upon Nf1 down-regulation. A: Schematic of
the pmirGLO vector used for testing Bmp2 3’UTR activity. B: Luciferase activity of the
Bmp2 3’UTR measured in STS26T-V(Nf1+/-), and STS26T-Nf1 KD cells normalized to
luciferase activity of the control vector. Paired t-test, n=3, *P<.05, **P<.01. Data presented
are mean of 3 independent experiments with 8 replicates per condition in each experiment
± S.D. C: Luciferase activity of the Bmp2 3’UTR normalized to activity of control vector
in conditional Nf1 KD cells. All conditional Nf1 KD cells show an increase in the Bmp2
3’UTR activity upon induction of Nf1 shRNA by doxycycline (2 µg/mL). Paired t-test, n=3,
**P<.01. Data presented are mean average of 3 independent experiments with 8
replicates per condition in each experiment ± S.D.
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4.4 Conclusions
From the mechanism-based experiments, we concluded that Nf1 regulates Bmp2
post-transcriptionally via regulation of the Bmp2 3’UTR, which results in an increase in
the cytoplasmic half-life of Bmp2 mRNA in MPNSTs. A further investigation into the
regulatory elements of the Bmp2 3’UTR will reveal the regulatory factors responsible for
stabilizing Bmp2 mRNA upon Nf1 deficiency. Thereby, we propose two notable posttranscriptional mechanisms of mRNA stability, i.e. adenylate-uridylate (AU)-rich elements
(ARE) and miR-response elements in the 3’UTR, which may be involved in regulation of
Bmp2 expression in Nf1-null MPNSTs.
Stability of the mRNA can be modulated by ARE and miR-response elements in
the 3’UTR (Cheneval et al. 2010). RNA-binding proteins bind the AU-rich motifs in the
3’UTR and stabilize or aid in degradation of the transcript. The importance of ARE sites
is underscored by studies which have established that loss of ARE-mediated control of a
given gene leads to severe pathologies such as developmental abnormalities and
tumorigenesis (Hodson et al. 2010; Ghosh et al. 2009; Hao & Baltimore 2009). The 3’UTR
of human Bmp2 is ARE-rich, containing thirteen classical AUUUA pentamer motifs along
with several non-canonical AU motifs [Fig 4.4(A)]. The heavy presence of ARE sites in
the Bmp2 3’UTR, which are well-conserved across species, is indicative of the role of this
region in controlling Bmp2 expression. Additional inquiry of the Bmp2 3’UTR by localizing
the specific region of Bmp2 3’UTR that is responsive to changes in the NF1 status will
identify ARE sites alongside RNA-binding proteins, involved in regulating Bmp2
expression in Nf1-null MPNSTs.
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Regulation by microRNAs (miRs) is another possible post-transcriptional
regulatory mechanism by which Nf1 regulates Bmp2 expression in MPNSTs. miRs are
20-24 nucleotides long noncoding RNAs that post-transcriptionally regulate gene
expression by mRNA degradation and/or translational repression. More than 50% of
mammalian RNAs are predicted to be controlled by miR-mediated regulation (Fabian et
al. 2010). Although the exact mechanism of post-transcriptional inhibition by miRs is not
well understood, the proposed model suggests that miRs bind target mRNAs via basepairing to miR-response elements in the 3’UTR and induce deadenylation, which results
in degradation of the transcript (Filipowicz et al. 2008). The 3’UTR of Bmp2 contains
many miR response elements with the highly conserved miR sites displayed in Figure
[4.4(B)]. We studied activities of miR-response elements of miR-17, miR-140, miR-214,
miR-374, and miR-378 on targeting of the Bmp2 3’UTR upon Nf1 knockdown. The
aforementioned miR-response elements were selected on the basis of degree of
conservation and published literature.

However, due to variable results between

experimental repeats we could not identify a miR or subset of miRs regulating changes
in Bmp2 expression upon Nf1 deficiency. We also studied alternative splicing of Bmp2
3’UTR between Nf1-KD and Nf1(+/-) conditions. Analysis of the poly(A) sites in the Bmp2
3’UTR by PCR of the poly(A)-associated regions in the cDNAs of STS26T-V(Nf1+/-) and
STS26T-Nf1 KD cells did not reveal any alternative splicing.
This is the first report of the mRNA half-life regulation by Nf1 in MPNSTs.
However, the exact mechanism, RNA-binding proteins or miRs, by which Nf1 deficiency
leads to up-regulation of BMP2 need be investigated. Many groups have shown the
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A

B

Figure 4.4: Human Bmp2 3’UTR with associated ARE and miR-response elements.
A: Schematic of the analysis of the Bmp2 3’UTR by courtesy of AREsite. Colored triangles
represent ARE sites, with their locations shown in the Bmp2 3’UTR. There are thirteen
canonical ARE sites (AUUUA) in the Bmp2 3’UTR, nine of which are conserved in mice.
B: Simplified schematic of the five broadly conserved families of miRs, with miR-response
elements in the Bmp2 3’UTR. The color key indicates the extent of base complementarity
of the given miR to the miR-response elements in the Bmp2 3’UTR. Red color denotes
7mer-m8, which is an exact match to positions 2-8 of the mature miRNA (the seed +
position 8). Blue color denotes 7mer-1A which is an exact match to positions 2-7 of the
mature miRNA (the seed) followed by an 'A'. Diagram is made by computational analysis
of miR sites in the Bmp2 3’UTR via TargetScan 6.0.
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deregulation of miRs and pertinent effects in NF1 and non-NF1 related MPNSTs
(Subramanian et al. 2010; Sedani et al. 2012; Masliah-Planchon et al. 2013).
Overexpression of miR-204 via its effects on the Ras pathway reduces proliferation,
invasion and migration in the ST88-14(Nf1-/-) and T265(Nf1-/-) cells in vitro, and reduces
growth and malignancy of the STS26T(Nf1+/-) cells in vivo (Gong et al. 2012). Inhibition
of expression of miR-214 and miR-10b in NF1-related MPNSTs decreases cell
proliferation and migration (Subramanian et al. 2010). Therefore, additional investigation
of the RNA-binding proteins and the associated ARE sites of the Bmp2 3’UTR combined
with a microRNAome profiling of Nf1(+/-) and Nf1-KD cells MPNST cells will not only
provide a comprehensive view of the mechanism of Bmp2 regulation by NF1, but will also
aid in identification of a genetic target of enhanced BMP2 signaling promoting migration,
invasion, and survival of MPNSTs.
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CHAPTER V: Discussion
MPNST is a rare form of cancer that comprises approximately 2% of all sarcomas
(Ng et al. 2013). Approximately half of all MPNST cases occur in association with NF1
disease (King et al. 2000), where the biallelic loss of Nf1 in Schwann cells is thought to
be responsible for transformation of neurofibromas to MPNSTs (Zhu et al. 2002). Given
that neurofibromas affect almost all NF1 patients (Compston 1994b; Huson 1989b) but
only 8-13% of these patients develop MPNSTs (Anghileri et al. 2006), the molecular path
from neurofibromas to MPNST formation is unclear. Mutations in the Nf1 RAS-GRD and
subsequent hyperactivation of downstream signaling pathways of RAF-MEK1/2-ERK1/2
and PI3K-AKT-mTOR are necessary but not sufficient to drive the transformation of
neurofibromas to MPNSTs (Cichowski et al. 1999; Zhu et al. 2002).
The genomic complexity of MPNSTs, in which multiple signaling pathways
cooperate to promote tumorigenesis, has limited treatment options for MPNST patients.
The failure of conventional chemotherapy by doxorubicin and ifosfamide (Zehou et al.
2013) and anti-RAS agents (Kim et al. 2013) has stimulated interest in rationally
developed targeted therapy for clinical management of MPNSTs. Thus far, targeted
therapies aimed at downstream signaling pathways of RAS have fared poorly in clinical
trials, although redesigned agents targeting the same pathways are currently under
investigation (Farid et al. 2014). To improve clinical outcomes for MPNST patients, a
comprehensive understanding of the biological events and gene expression changes
independent of Ras signaling, in the setting of NF1 is imperative.
The goal of this study was to utilize gene expression profiling followed by molecular
and biochemical studies, to identify a novel target of Nf1 regulation independent of RAS-
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GRD, understand gene regulation, and therapeutic utility of multiple targeted pathways to
improve clinical outcomes for NF1-related MPNSTs. To this end, we have identified
BMP2-SMAD1/5/8 pathway, independent of the RAS-MEK1/2-ERK1/2 axis (Sun et al.
2013) to be associated with invasion, migration and metastatic properties of MPNST cell
lines. I identified a novel regulatory mechanism of mRNA stabilization by NF1. Most
importantly, I developed a combinatorial therapeutic approach that reduces the cellular
viability of MPNST cells by targeting BMP2 and MEK1/2 with LDN-193189 and
selumetinib, respectively.
Anti-tumor interactions of LDN-193189 and selumetinib were evaluated in multiple
MPNST cell lines including physiologically relevant low passage NF1-null MPNST cells.
Unsurprisingly, single treatment with LDN-193189 resulted in reversal of migratory and
invasive properties of MPNST cells regardless of passage number. The efficacy of
combinatorial treatment with LDN-193189 and selumetinib on cell viability was enhanced
in the low passage cells as compared to the high passage cells. However, combination
treatment did not result in a significant decrease in cellular migration or invasion of these
cells. This can be due to the strong inhibitory effect of LDN-193189 on migration and
invasion of MPNST cells, therefore addition of selumetinib does not result in a significant
change in the migratory and invasive potential of these cells.

Decreasing the

concentration of LDN-193189 in the combinatorial treatments may provide a better
assessment of the combinatorial effects of these drugs on cellular migration and invasion
of MPNSTs.
I found that the combination of LDN-193189 and selumetinib synergistically
inhibited cell viability in all of the tested MPNST cell lines through possible off-target
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effects, independent of passage number or NF1 status. The cell viability GI50 for LDN193189 was at least 10-20 times higher than the biochemically relevant concentration
required to inhibit BMP2-SMAD1/5/8 signaling. With the demonstrated lack of adverse
side effects of LDN-193189 in animal studies (Yu et al. 2008), the inhibition of cell viability
by LDN-193189 at higher doses may provide an additional therapeutic benefit in
treatment of MPNSTs. The decrease in viability of MPNST cells was associated with
increased cleavage of Poly(ADP- ribose) polymerase (PARP), a marker of cell death,
detected by western blots in combination treatment as compared to single treatments with
LDN-193189 or selumetinib (data not shown). The presence of cleaved PARP fragments
(~89 kDa) is indicative of cytotoxicity induced by these agents. Nonetheless, we cannot
delineate the precise mechanism of cytotoxicity (apoptosis, autophagy or necrosis)
without additional assessment of caspase activity, and/or annexin V staining. Likewise,
cytostatic effects of the combinatorial treatment cannot be ruled out as we did not test for
any markers associated with cytostasis upon treatment of MPNST cells.
In our pharmacology studies, I also assessed the efficacy of targeting the
PI3K/AKT/mTOR pathway regulated by RAS in MPNSTs.

Additionally, BMP2-

SMAD1/5/8 pathway has been reported to interact with the PI3K/AKT/mTOR pathway to
induce invasiveness in cancer subtypes (Kang et al. 2010). Treatment with a dual
PI3K/mTOR inhibitor VS-5584 (0.3µM) for 3 hours promoted cell death by presence of
cleaved PARP fragments in ST88-14(Nf1-/-) cells; however, addition of LDN-193189
and/or selumetinib to VS-5584 treated cells did not significantly increase cell death (data
not shown).

These therapeutic studies suggest that targeting of BMP2-SMAD1/5/8

pathway by LDN-193189 in combination with inhibition of MEK1/2-ERK1/2 signaling by
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selumetinib provides an effective strategy to reduce the cell viability of MPNSTs, however
further analysis of the combinatorial interaction of both the agents on migration and
invasion is warranted.
To explore the mechanism by which NF1 deficiency leads to increased expression
of Bmp2, we analyzed the transcriptional regulation of Bmp2 by promoter, 3’UTR, and
transcript half-life studies. I identified a post-transcriptional regulatory mechanism by
which NF1 regulates the 3’UTR of Bmp2. The 3’UTR of Bmp2 exhibits increased activity
upon knockdown of Nf1 leading to increased half-life and stability of Bmp2 mRNA. I
determined that Bmp2 mRNA half-life in Nf1 heterozygous conditions is approximately 2
hours, which virtually doubles upon knockdown of Nf1. mRNAs with short half-lives such
as Bmp2, have fast induction and repression rates (Bolognani & Perrone-Bizzozero 2008)
and are known to respond to changes in transcription more rapidly than those with longer
half-lives (Ross 1995). Importantly, stabilization of mRNAs with short half-lives can result
in dramatic changes in gene expression, hence protein levels (Hargrove & Schmidt 1989).
Accordingly, the increased stability of the Bmp2 mRNA upon Nf1 knockdown may permit
a prolonged translational window, leading to increases in BMP2 protein levels and its
functional effects on migration and invasion. I noticed a strong association between the
increase in Bmp2 mRNA half-life and steady-state mRNA levels. These findings agree
with a previous report where human Bmp2 mRNA decay rate correlates with endogenous
Bmp2 mRNA levels (Fritz et al. 2004). The unusually high degree of conservation of the
Bmp2 3’UTR (Fritz et al. 2004) coupled with the ample presence of ARE sites and miRresponse elements within this region, is suggestive of a strictly regulated region which is
instrumental in controlling Bmp2 expression levels. The regulation of transcript stability
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by NF1 is a novel concept that need be further explored. Although there is an overall
down-regulation of genes in MPNST tissue samples as compared to the benign forms of
neurofibromas (Miller et al. 2009), our gene expression profiling study identified
overexpression of several candidate genes upon NF1 deficiency such as SOX9, STAG1,
POU5F1, VEGFC, EDN1, CXCL3, etc. mRNA stabilization may be the mechanism of
increased expression of other genes up-regulated by knockdown of Nf1 in MPNST cells.
Analysis of the transcript half-lives and 3’UTR regions of these up-regulated genes may
potentially identify common cis- and trans-acting elements regulated by NF1 that can be
therapeutically targeted in MPNSTs.
Overall, this study has shown the feasibility of targeting BMP2-SMAD1/5/8
signaling in combination with MEK1/2-ERK1/2 inhibition in MPNSTs.

Additionally,

targeting of post-transcriptional regulatory elements involved in regulation of Bmp2 3’UTR
by NF1 provides an alternative genetic target to precisely inhibit BMP2 expression and
its functional effects on cell migration and invasion in MPNSTs. A model diagram of the
proposed combinatorial targeting approach presented in this study with the goal of
improving clinical outcomes for MPNST patients is presented in Fig 5.1.
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Figure 5.1: Diagram summarizing the proposed combinatorial targeted therapeutic
approach for treatment of MPNSTs. NF1 attenuates RAS and associated downstream
signaling cascades by accelerating hydrolysis of RAS-GTP to RAS-GDP. NF1 posttranscriptionally regulates Bmp2 leading to suppression of BMP2-SMAD1/5/8 signaling
pathway. NF1 deficiency leads to constitutive activation of RAS-MEK1/2-ERK1/2, and
BMP2-SMAD1/5/8 signaling pathways, enhancing the tumorigenic properties of
MPNSTs. Combinatorial targeting of MEK1/2 by selumetinib (AZD6244) and BMP2 by
LDN-193189 or inhibition of Bmp2 post-transcriptional regulatory elements reduces the
increased survival of MPNSTs, however does not affect the migratory and invasive
characteristics of malignant MPNSTs.
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Neurofibromatosis type I (NF1)-deficient malignant peripheral nerve sheath tumor
(MPNST) is an aggressive tumor for which the standard treatment is surgical removal
with wide margins, often leaving behind cancer cells needing chemotherapy. RAS-GRD
is the most widely studied functional target of NF1 implicated in tumorigenesis, however,
therapeutic interventions targeting RAS activity have met with limited success. Using
gene expression profiling, our lab identified BMP2-SMAD1/5/8 signaling pathway as a
therapeutic target in MPNSTs, independent of the NRAS and MEK1/2 regulation. The
overall goal of my research was to validate the significance of BMP2 in MPNSTs in novel
cellular models, study the combinatorial effects of BMP2 and MEK1/2 inhibition, and use
the regulation of BMP2 transcriptional control to define mechanism-based rational targets
of BMP2 signaling, to treat NF1-related tumors.
Biological aggressiveness of MPNSTs is characterized by its highly motile and
invasive nature. I presented a unique approach that targets not only the motility and
invasive capability but also growth and proliferative potential of MPNSTs, by inhibition of
BMP2-SMAD1/5/8 and RAS-MEK1/2-ERK1/2 signaling pathways in MPNST cell lines.
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By using physiologically relevant cell models that simulate MPNST condition in vivo, I
have shown that combinatorial targeting of BMP2 and MEK1/2 pathways results in
reversal of malignant features of MPNST cell lines. Additionally, I have identified a novel
regulatory mechanism by which NF1 mediates BMP2 transcript stability. The targeted
inhibition of the molecular components involved in stability of the Bmp2 3’ UTR by NF1,
represents an alternative approach of genetic targeting in MPNSTs. In summary, I have
presented two independent methodologies of therapeutically targeting BMP2-SMAD1/5/8
signaling in MPNSTs.
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